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ABSTRACT 
 
TARGETED PROTEOMICS AND BIOCHEMICAL FRACTIONATION: 
NEW TOOLS FOR DECIPHERING THE SYNAPSE IN SCHIZOPHRENIA 
 
Matthew L. MacDonald 
 
Advisors: 
Chang-Gyu Hahn 
Ian A. Blair 
 
Schizophrenia is a chronic and debilitating psychiatric illness affecting 
approximately 1% of the world’s population for which there is no cure and treatment 
options are limited.  Poor understanding of disease pathology and the difficulty in 
modeling psychiatric symptoms in animal models has hindered the search for a cure.  
Despite these difficulties great progress has been made on several fronts. Genetic studies 
have identified risk genes for disease, while fMRI and histology experiments have 
located brain regions with altered activity and cytoarchitecture. Pharmacology, molecular 
and immunology studies have identified receptor signaling pathways that are perturbed as 
well.  
One of the biggest challenges currently facing the field is elucidating the 
mechanisms linking genetic and environmental risk to the altered processes observed in 
the brains of schizophrenic patients.  One approach to this question may be to investigate 
the postmortem brain tissues of patients. The goal of this thesis is to use mass 
spectrometry based proteomics to investigate the expression and partitioning of 
postsynaptic density proteins in these tissues. The postsynaptic density is implicated in 
disease pathology by genetic, cytoarchitecture and molecular studies. Thus, there is a 
good possibility that its protein composition reflects the crossroads of genetic risk and 
dysregulated molecular and developmental processes.   
vi 
 
A qualitative analysis of the human postsynaptic density was performed to catalog 
the proteins therein.  Data from this experiment was harnessed to develop a mass 
spectrometry method for the targeted quantification of over 200 synaptic proteins. This 
method was then used to validate subcellular fractionation of human postmortem brain 
tissue to capture synaptic microdomains. Finally, this targeted mass spectrometry method 
was utilized to quantify synaptic protein expression and PSD partitioning in postmortem 
brain tissues of subjects and patients. The enrichment of PSD proteins was elevated in 
tissue from schizophrenic subjects compared to controls, while total protein expression 
was unaltered. This data suggests that partitioning, not expression, of postsynaptic 
proteins is altered in schizophrenia.   The results of this study demonstrate the power of a 
targeted mass spectrometry approach and provide an important context in which to study 
the dysregulation of synaptic processes in schizophrenia.  
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GENERAL INTRODUCTION 
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1. Schizophrenia  
Schizophrenia (SCZ) is a chronic and debilitating psychiatric illness affecting 
approximately 1% of the world’s population1, 2.  Disease etiology is not currently 
understood, and while some symptoms can be controlled with therapeutics, no cure 
exists.  
SCZ has broad diagnostic criteria and is defined by cognitive, sensory and 
emotional disturbances of mind.  Schizophrenia-diagnosed mathematician Dr. John Nash 
described his experience with the disease thus: 
 
“…I started to think I was a man of great religious importance, and to hear voices 
all the time. I began to hear something like telephone calls in my head, from 
people opposed to my ideas. ...The delirium was like a dream from which I 
seemed never to awake.”3 
 
SCZ symptoms are multilayered, and can be divided into three groups for research 
purposes: 1) positive symptoms, 2) negative symptoms and 3) cognitive symptoms.  
Positive symptoms are disturbances of perception and thought content, making it difficult 
for patients to interpret or accurately compare their own beliefs to reality. Typical 
manifestations include hallucinations (often auditory), along with delusions and chaotic 
thinking (inability to organize thoughts and associations), which often results in bizarre 
behavior and speech. Negative symptoms include alogia, apathy and anhedonia, which 
can compromise the ability to perform normal social behaviors4, 5. Patients can withdraw 
socially, lack the ability to feel or express emotion and have difficulty communicating.   
Cognitive symptoms encompass impairments in working memory and executive function. 
This final class is usually the most consistent over time, persisting even when positive 
and negative symptoms are controlled or absent.  
 Disease onset typically occurs in the age range of the late teens to early twenties, 
with women having a later average onset age as compared to men1, 2. A “prodromal” 
period, categorized by cognitive decline, along with mild positive and negative 
symptoms, typically precedes full emergence of disease symptoms6. However, many 
prodromal symptoms overlap with other psychiatric diseases, as well as with normal 
adolescent affects. Thus, they are not predictive and often only diagnostically helpful in 
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retrospect7. Additionally, the full array of disease symptoms do not usually present 
simultaneously.  Positive and negative symptoms can fluctuate in intensity, while 
cognitive symptoms tend to be more consistent. After the first interaction with a 
psychiatrist, months or even years can be required to establish the pattern and persistence 
required for an accurate diagnosis. For those who have been diagnosed with SCZ, the 
long-term outlook points toward an arduous track. Only 30% of those diagnosed with 
SCZ are able live without assistance, 6% are homeless, 6% are incarcerated and 15% will 
commit suicide89.  
 While therapeutic agents can control some of the symptoms, there is no cure for 
the disease. Positive symptoms are the most likely to respond to pharmacologic 
intervention, while negative symptoms are less responsive and cognitive symptoms are 
largely resistant to intervention. Complicating pharmacologic interventions are the severe 
side effects that can accompany therapeutics, which patients often find intolerable.  
Examples of such side effects include tardive dyskinesia, which can arise as a side effect 
of high potency typical neuroleptics, and weight gain, which can be a side effect of some 
atypical neuroleptics.   The presence of severe side effects is notable in that they can 
contribute to medication non-compliance and recurrent hospitalization 10, 11.   
SCZ has been demonstrated to have a strong genetic component12, 13, with 50% of 
monozygotic twins and 6-17% of first-degree relatives sharing the disease14.  
Additionally, a variety of environmental factors, including exposure to infectious, 
autoimmune, toxic, nutritional, or traumatic insults during pre- and/or postnatal 
development, have been proposed as contributing factors accounting for a portion of what 
cannot be explained by genetics alone15. Current theories of disease etiology postulate 
that genetic vulnerabilities and environmental insults converge to impair multiple brain 
circuits during development, manifesting full disease symptoms almost two decades into 
life.  
2. Schizophrenia is a disease of mind 
SCZ is a disease of mind. In his autobiography In Search of Memory, Nobel 
laureate Dr. Eric Kandel described mind as: 
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“… a set of 
operations carried 
out by the brain, 
much as walking 
is a set of 
operations carried 
out by the legs, 
except 
dramatically more 
complex.”16 
 
In the brain, 
neural circuits 
connecting 
different regions 
carry out the 
operations. To 
investigate a disease of mind is to study the biology of the underlying brain regions and 
circuits that perform disturbed operations. The multiple dimensions of mental operations 
perturbed in SCZ suggest that several brain regions and circuits are involved, likely in a 
complex manner. Advances in neuroimaging technologies, most notably functional 
magnetic resonance imaging (fMRI), have allowed researchers to look into the active 
brain, while histological techniques have made it possible to investigate neuronal 
cytoarchitecture in the postmortem brain tissues of patients.  Using these techniques, 
skilled and dedicated researchers have linked specific brain areas to certain disease 
features, and cataloged neuroanatomical irregularities. Figure 1-1 depicts several brain 
areas that have been implicated in SCZ, their suggested relationships to particular 
symptoms and anatomical findings in diseased tissue.   
2.1 Cognitive symptoms are a core feature of disease  
Although positive symptoms tend to be more prominent, cognitive symptoms are 
more persistent and difficult to treat. Cognitive symptoms are observed in a majority of 
patients, present independently from psychotic symptoms17, and are endure throughout 
Figure 1-1. Relevant brain areas in schizophrenia. The diverse 
symptoms of schizophrenia implicate multiple brain areas and circuits. 
The prefrontal cortex receives and sends to/from many of these brain 
areas. These areas, their connections, functions and associated 
symptoms are depicted.   
5 
 
the lifespan18-21.  Additionally, milder cognitive deficits can be observed in non-SCZ 
relatives22, suggesting a genetic link, which is expanded on further below. Finally, 
cognitive symptom severity is a strong predictor of poor functional recovery17, 23. Thus, 
cognitive symptoms are now considered to be a core feature of the disease. 
Working memory, the ability to transiently maintain and process information, and 
executive function, the coordination of different brain areas and neural processes to guide 
thoughts and actions, are the most intensely studied of the cognitive symptoms.  More 
than any other brain region, the prefrontal cortex (PFC) is thought to be the primary 
orchestrator of these functions24.   
2.2 The prefrontal cortex is the seat of executive function.  
 The PFC is the anterior section of the frontal lobes, and is responsible for 
heterogeneous mental functions. It can also be defined as the area of the cerebral cortex 
that receives inputs from the thalamic mediodorsal nucleus.  In primates, the PFC is 
differentiated from the rest of the frontal cortex by the presence of a well-developed 
granular layer 4.  PFC size distinguishes humans within the primate family, representing 
29% of the total human cortex, while comprising only 17% in chimps and 11.5% in 
macaques25 24. The general cytoarchitecture of the PFC is similar to that of other cortical 
regions, consisting of stratified layers of cells with regular and systematic connections 
(Figure 1-2). Within this basic template, the PFC is architecturally diverse. Broadmann 
used classical histological techniques to identify 10 distinct regions, and modern 
techniques have identified further anatomical diversity within these areas. The PFC 
receives inputs from a wide variety of brain areas, most notably the thalamus, brain stem 
tegmentum, amygdala, hippocampus, cingulate cortex, cerebellum, locus coeruleus, 
ventral tegmental area and the raphe.  In turn, the PFC extends projects to multiple 
structures, including the thalamus, hippocampus and other cortical regions. The PFC is 
also extensively connected to the motor and sensory cortices24.  The PFC is therefore, a 
demonstrably vital hub for motor, spatial, memory, internal state and emotional 
information  
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PFC cytoarchitecture is highly organized and complex. Like all cortical areas it is 
composed of stratified orders of cells with regular connective patterns (Figure 1-2). 
Pyramidal cells, excitatory glutamatergic neurons, constitute 75% of these layers24. 
Generally speaking, neurons in different layers project to different brain regions. Those in 
layers 2 and 3 project to other cortical regions, 5 to the striatum and brain-stem, 6 to the 
thalamus. Likewise, projections from other brain areas tend to target discreet layers. Most 
of the other 25% of PFC neurons are inhibitory GABAergic interneurons that both 
Figure 1-2. Dorsolateral prefrontal cortex cytoarchitecture and NMDA receptor 
signaling is perturbed in schizophrenia. A. “an unstained coronal block cut immediately 
anterior to the corpus callosum through the left hemisphere of a postmortem human brain.” –
Lewis et al. 200843. B, Cortical layers and two basic neuron types. 1. GABAergic inhibitory 
neurons synapse locally within the cortex to regulated and coordinate pyramidal neuron 
activity. 2. Excitatory glutamatergic pyramidal neurons represent 75% of the neuronal 
population of the DLPFC. Pyramidal neuron dendrites receive information locally and project 
axons to other cortical areas, the striatum or thalamus, depending on the layer. The majority of 
layer 2 and 3 pyramidal neurons project to other cortical areas. C. Dendritic spine density is 
decreased in layers 2 and 3 of the DLPFC in schizophrenia35, 43. 3, depicts a dendrite in a 
normal subject and 4, a dendrite in a schizophrenia subject. D, depicts some of the major PSD 
proteins58 and recent findings from the Hahn lab84 of altered protein-protein interactions and 
signaling. 5. NRG1 induced activation of ErbB4 is increased as is ErbB4 – PSD95 – NR 
association in schizophrenia (6.). 7. NMDA/glycine induced NR activation is decreased in 
schizophrenia, while ErbB4 attenuation of NR activation is increased. As PSD95 complexes 
ErbB4 to NR and PSD95 – ErbB4 association is required for ErbB4 activation; these results 
suggest that altered protein composition or interactions at the PSD could contribute to NR 
hypofunction in schizophrenia. 8. src kinase activity is decreased in schizophrenia as well, 
also likely contributing to NR hypofunction.  
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receive and project within the same PFC area24. Interneurons serve to coordinate 
interneuron function, participating in important inhibitory feedback loops26.  
 Joaquin Fuster has proposed that the PFC orchestrates three executive function 
processes: 1) Complex action (planning), 2) Goal-oriented behavior and 3) Executive 
attention.  In this theory, the PFC is thought to process information and conduct activity 
from numerous other brain areas, culminating in the ability to perform executive 
function. This view fits well with the findings of PFC cytoarchitecture and connections 
discussed above. Thus, the PFC is a compelling target in which to study the biology of 
SCZ, as a plethora of functions to which it is connected are perturbed, and the complexity 
of the PFC structure mirrors the complexity of the disease.  fMRI and cytoarchitectural 
studies have consistently implicated three brain areas in connection with the cognitive 
symptoms of SCZ: the dorsolateral prefrontal cortex (DLPFC), anterior cingulate cortex 
(ACC) and hippocampus42 43.  The remainder of this introduction will focus on the 
DLPFC, as the studies described in the following chapters were performed using tissue 
from this area of the PFC.  
2.3 Altered DLPFC activation is associated with impaired working memory in 
schizophrenia  
Neuroimaging studies have implicated dysregulated DLPFC functioning in 
connection with cognitive symptoms of SCZ. Specifically, alterations in both blood flow 
and glucose utilization in the DLPFC have been observed in SCZ patients performing 
working memory and executive function tasks. During low difficulty tasks, increased 
DLPFC blood flow and glucose utilization have been observed, with no performance 
deficits.   During more difficult tasks, however, a decrease in DLPFC blood flow and 
glucose utilization was observed, and performance deficits were exhibited27 28. These 
performance deficits are not reliably observed during resting, and appear to be unique to 
SCZ among neuropsychiatric diseases29 30. 
 In addition to task-dependent alteration in DLPFC activity, deficits in brain tissue 
have been observed in SCZ patients. Meta-analyses of reports on grey matter volume in 
SCZ indicate moderate loss in the PFC and hippocampus31 32. The combination of task-
8 
 
related and grey matter deficits implicates the DLPFC in cognitive symptoms, although 
the exact mechanisms underlying the connections between symptoms and anatomy are 
not yet clear.  However, PFC histological and molecular investigations have begun to 
provide some insight into this question.   
2.4 Synaptic connectivity of pyramidal neurons is decreased in schizophrenia   
Three observations, repeated by several groups across different cohorts, point to 
decreased synaptic connectivity, without neuronal loss, in the DLPFC, proving a 
compelling explanation for decreased grey matter volume.  1) Neuropil, the connective 
processes between neurons, are decreased in SCZ while the total number of neurons 
appears to be unaltered33 34. 2) The dendritic spine density of pyramidal neurons, per 
dendrite length, in DLPFC layers II and III is decreased in SCZ35 36. It is important to 
note that decreases in dendritic spine density and neuropil are not limited to the DLPFC 
and extend to other brain regions with impaired function in SCZ including the visual, 
auditory and temporal cortices and the hippocampus 37-39. 3) Pyramidal neuron cell 
volume and dendrite length is also decreased in SCZ in the DLPFC and other affected 
brain areas. These observations are not as large or consistent as the decreases in neuropil 
and spine density. Additionally, efforts to link decreased spine density to decreases in 
pyramidal neuron cell volume in several brain areas in SCZ have returned modest or 
insignificant correlations37 35 40 41. 
 To summarize the findings outlined above, pyramidal neuron dendritic spine 
density is decreased in layers 2 and 3 of the DLPFC in SCZ, while the total number of 
pyramidal neurons is unaltered.  This decrease in spine density is per spine length and 
thus is independent of decreased length or branching. Pyramidal cell volume is also 
decreased to a lesser extent in these layers, but does not correlate strongly with decreased 
spine density.  Importantly, the few studies that have directly counted axon terminals in 
cortical regions of SCZ tissues have observed a loss similar to spines37.   
The fact that dendritic spine loss is observed across several cortical areas suggests 
that it could represent the end point of a common pathology.  The loss of synaptic 
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connectivity likely explains the decrease in cortical grey mater and is widely believed to 
underlie the function deficits observed in the DLPFC, and other cortical areas, of SCZ.  
The number of synaptic connections, and spines, increases steadily through 
development, reaching its zenith in late childhood/early adolescence and decreases 
gradually through adulthood into old age6, 42.  This decrease is referred to as “pruning”. 
Increased pruning is one of several hypotheses put forward to explain the decreased spine 
density observed in the tissues of elderly SCZ patients investigated6, 42. An alternate 
hypothesis posits that synaptic numbers in SCZ patients simply never reach the amounts 
present in normal individuals42. These hypotheses are difficult to test, as brain tissues 
from normal children are extremely rare and SCZ diagnosed children are, for all practical 
purposes, nonexistent. Never the less, both of these hypotheses hinge upon aberrant 
neuroplasticity, the term that describes the broad mechanisms by which neurons form, 
strengthen and prune synaptic connections.  The involvement of neuroplasticity in SCZ 
pathology is well supported by evidence from genetic, pharmacological, behavioral and 
immunological studies. A brief primer on neuroplasticity, postsynaptic glutamate 
signaling and the synaptic microdomain in which it occurs, the postsynaptic density 
(PSD), is required to put this evidence in context.  
3. Glutamate signaling at the postsynaptic density is an essential component of 
neuroplasticity  
The constant forming, strengthening and pruning of synapses in the brain are 
crucial aspects of brain functioning, and are essential for learning and memory43. 
Neuroplasticity describes the progression from short-term processes, such as the ligand 
receptor interactions and membrane depolarization, through long term consequences, the 
changes in gene expression that ultimately result in neuron and synapse structure 
remodeling.  Glutamate signaling is central in initiating and maintaining this process.  
3.1 Glutamate receptors 
Glutamate signaling is critical for the formation and maintenance of synaptic 
connections in both the developing and mature brain44.  Glutamate acts through 
ionotropic and metabotropic receptors to mediate Ca2+ influx, which activates signal 
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transduction cascades. Cascades include kinases and phosphatases that can alter the 
phosphorylation state of receptors, ion channels, transcription factors and other signaling 
proteins with diverse and far-reaching effects. Three families of glutamate receptors play 
a role in regulating neuroplasticity.   
The N-methyl-D-aspartate receptor (NR) is a slow-acting ionotropic glutamate 
receptor, named for the ligand to which it selectively responds45, 46.  The NR is a 
heterotetramer comprised of subunits from three families: two obligate NR1 subunits, of 
which there are eight splice variants, and two NR2 subunits, of which there are 4 types 
(A,B,C and D)45, 47-49. The expression of alternate NR1 splice variants regulates 
trafficking to the synapse50, while NR2 subunits differ in their affinity for ligand binding, 
channel conductance, and downstream signaling51, 52. A third family of NR subunits 
(NR3) suppresses glutamate-induced currents53.  
2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl propanoic acid (AMPA) and kainite 
receptors are also ionotropic receptors, composed of four subunits. AMPA receptors are 
primarily postsynaptic while kainite receptors have both pre- and post-synaptic functions 
(Ref).  Conductance of these tetramers is determined by subunit compositions48.  
Activated ionotropic glutamate receptors are permeable to Na+ and K+ and Ca2+.  
NR activation requires the presence of both glutamate and glycine, as well as the absence 
of Mg2+ in the channel pore.  Mg2+ removal is voltage dependent, mediated by AMPA 
receptor-dependent membrane depolarization.  Thus, the NMDA and AMPA receptor 
function together as a coincidence detector, which is believed to be central for tightly 
regulating neuroplasticity54.   
A third family of glutamate receptors, metabotropic glutamate receptors (mGluRs), 
also have an important role in regulating glutamate release and NR activity.  mGluRs are 
seven transmembrane G-protein coupled receptors.  Eight subtypes and three family 
groupings have been identified.  Group I mGluRs (mGluR1 and mGluR5) activate the 
production of cyclic AMP and arachidonic acid via phospholipase C (PLC)55, while 
group II (mGLuR2 and 3) and group III (mGluRs 4,6,7 and 8) inhibit adenylate cyclase 
activity. Postsynaptic mGluRs can impact neuroplastic signaling cascades by regulating 
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the release of intracellular calcium stores. Additionally, group I mGluRs are complexed 
to the NR, with the ability to regulate its activity and permeability56, 57.    
In summary, diverse receptor families with robust interactions mediate glutamate 
activation of neuroplasticity.  Signaling molecules and scaffolding proteins facilitate 
receptor interactions in the postsynaptic density (PSD)58. 
3.2 The postsynaptic Density   
The postsynaptic density (PSD) is a thickening of the dendritic membrane, 
sometimes considered to be an “open organelle”58.  The PSD is rich in glutamate 
receptors, as well as scaffolding proteins and kinases (Figure 1-2)58. Here, interactions 
and signaling events proceed in a complicated, non-linear fashion to integrate the pre-, 
post- and extra-synaptic signaling events described above that regulate the 
neuroplasticity-defining transcription, translation and protein trafficking events as well as 
cytoskeletal changes44, 58-60. The PSD is a fluid, but highly organized structure. This 
organization is mediated by several families of scaffolding proteins58, 59 that tether 
glutamate receptors to the membrane, linking them with other receptors, channels and 
signaling molecules. Several of these scaffolding proteins also have important roles in 
receptor trafficking58.  
4. Aberrant neuroplasticity and NMDA receptor function in schizophrenia   
Several lines of evidence, from pharmacological, immunological and genetic studies 
reviewed below, have convincingly linked NR hypofunction to various symptom 
domains of SCZ. 
4.1 Pharmacologic evidence for NMDA receptor hypofunction in schizophrenia 
Pharmacological studies provided the first evidence for NR hypofunction in SCZ.  
The noncompetitive NR antagonists phencyclidine (PCP) and ketamine produce positive, 
negative and cognitive symptoms in normal human subjects, and exacerbate these 
symptoms in SCZ subjects for prolonged periods following NMDA antagonist 
administration61, 62. PCP and ketamine also induce behavioral correlates of positive and 
negative symptoms in non-human primates and rodents, such as cognitive and 
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sensorimotor gating impairments, hyperlocomotion and social impairments63.Importantly, 
treatment with antipsychotic drugs has been demonstrated to ameliorate these 
behaviors64. 
Concordant with the evidence that antagonizing NR function produces the 
behavioral and cytoarchitectural abnormalities observed in SCZ, agents that boost NR 
functions, such as D-serine, sarcosine and N-acetyl-cysteine, have demonstrated value as 
adjunct therapies65-68. Additionally, one meta-analysis of clinical trials reports that NR 
function-boosting agents have exhibited efficacy in improving negative symptom 
treatment outcomes when administrated alongside typical antipsychotics69.  
4.2 NMDA receptor encephalopathies produce schizophrenia-like symptoms  
Recent characterizations of NR encephalopathies also provide compelling 
evidence for NR dysfunction in SCZ.  NR autoantibodies producing a SCZ-like 
syndrome in patients that is completely resolved following dialysis, provides further 
supporting evidence for NR involvement in SCZ70. Furthermore, studies in rats have 
demonstrated that NMDA antibodies obtained from encephalopathy patients internalize 
NRs, decrease NR-mediated currents and impair learning and memory71.   
4.3 Schizophrenia risk genes impact NMDA receptor and PSD signaling 
Many of the most reproducibly identified SCZ risk genes are directly connected to 
NR signaling at the PSD72-7677. Four well studied examples of NMDA-associated proteins 
that are also risk genes include disrupted in SCZ 1 (DISC1), regulator of G-protein 
signaling 4 (RGS4), neuregulin 1 (NRG1) and v-erb-a erythroblastic leukemia viral 
oncogene homolog 4 (ErbB4)72, 74, 78-80 81, 82. NRG1-ErbB4 signaling attenuates NR 
activity through an Src-dependent pathway83, 84. DISC1 has been shown to regulate 
trafficking of NRs85 , and RGS4 attenuates mGluR5 activation, which complexes to the 
NR via PSD scaffolding proteins81, 82.  
From a broader standpoint, recent bioinformatics analyses of proteins identified in 
human PSD enrichments and mouse immune-precipitated (IP) PSD95 complexes 
revealed the presence of a significant number of risk genes for multiple neuropsychiatric 
diseases relative to the total genome76, 86. Of these diseases, risk genes for SCZ were 
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found to be the most significantly represented among all known risk genes for 
neuropsychiatric illnesses75, 86, 87.   
4.4 NMDA receptor activity and PSD signaling are perturbed in PFC tissue of 
patients 
The pharmacological and immunological evidence presented above strongly 
suggest the involvement of NR hypofunction in SCZ symptoms.  Genetic studies have 
identified a number of risk genes that indirectly mediate PSD and NR activity, trafficking 
and downstream signaling72, 74, 77.  Many of the genetic investigations share the goal of 
identifying risk genes that could explain disease symptoms and neuronal cytoarchitecture, 
mediated through neuroplasticity and developmental processes.  The PSD has been 
repeatedly implicated in SCZ, as seen in the vast array of risk genes participating in PSD 
processes, the prominent role of the PSD in NR activity regulation and the complexity of 
PSD signaling processes75, 76, 86. Based on the multiplicity of PSD-related findings, 
several researchers have suggested that the PSD could act as a point of convergence for 
the genetic and environmental risk factors, which thereby manifest themselves impaired 
neuroplasticity and resulting in the anatomic abnormalities believed to underlie disease 
symptoms75, 78, 88 89. However, the NR hypofunction and PSD hub hypotheses have been 
difficult to test directly in human patient tissues. Utilizing a novel ex-vivo stimulation 
paradigm, our lab has investigated NR activity, downstream signaling and protein 
interactions in human patient tissues.  
 NMDA/glycine-induced NR activation was found to be attenuated in post-mortem 
PFCs of SCZ patients as assessed by three independent metrics: NR2A tyrosine 
phosphorylation and recruitment of PLCγ and nNOS490. Surprisingly, MK-801 binding 
capacity of synaptic membranes and NR1/PSD-95 complexes was enhanced, as was the 
amount of NR1 in PSD enrichments as measured by Western Blot.  NR association with 
its signaling partners, phospholipase C gamma (PLCγ)  and protein kinase C gamma 
(PKCγ) were significantly decreased in patient PSDs. Additionally, NR mediated 
activation of PKCγ, protein tyrosine kinase 2 (Pyk-2), and the tyrosine kinase Src was 
also reduced in patient tissues (Banerjee et al. in review).  To test if such changes in 
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kinase association and activation could account in part for dysregulation of NR function 
in SCZ, Src activity was assessed independent of its upstream kinases.  Indeed, src 
activity was significantly decreased in response to src-SH2 domain binding peptides in 
the synaptic membranes of the SCZ patient group (Banerjee et al. in review).  
 Activity of the risk gene ErbB4 was also altered in SCZ patients.  NRG1 
activation of ErbB4 signaling was dramatically increased in SCZ subjects, as was NRG1-
ErbB4 attenuation of the NR.  Interestingly, these changes were accompanied by a 
significant enhancement in the association of ErbB4 with PSD-95 in SCZ subjects90.  
Since coupling between ErbB4 and PSD-95 is crucial for its activation91, 92 this study 
suggests that altered protein-protein interactions could contribute to altered ErbB4 
signaling. 
4.5 Attenuation of NMDA receptor activity reduced cortical spine density  
  Numerous studies have demonstrated that attenuating NR function, either directly 
or through proximal proteins or pathways, can result in decreased dendritic spine density. 
The complete knockdown of NR1 from pyramidal neurons in the cortex results in a 40% 
decrease in spine density in layers 2 and 393.  In a more subtle manipulation of NR 
activity in vivo, Balu et al. demonstrated that decreased amounts of the NR co-agonist 
serine (induced by serine racemase knockout) decreased cortical spine density. Decreased 
amounts of the endogenous NR antagonist glycine (induced by knocking out one copy of 
glycine transporter GlyT1) increased cortical spine density94. 
4.6 The link between genetic risk for disease and PSD/NMDA receptor 
hypofunction is implied, but has not been observed  
Pharmacological, behavioral and immunological studies have demonstrated that 
attenuation of NR function produces a variety of SCZ-like symptoms in humans and their 
behavior corollaries in animals. Transgenic studies in mice have demonstrated that both 
extreme complete loss and subtle attenuation of NR function can mimic the decreased 
spine density observed in SCZ.  The ex-vivo stimulation experiments performed in the 
Hahn lab directly observed NR hypofunction the tissues of SCZ patients. Together these 
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studies powerful evidence that NR hypofunction can acutely induce SCZ like symptoms 
and impact neuronal development resulting in dendritic spine loss.  
Genetic studies have identified a SCZ risk genes, many of which are directly 
involved in NR and PSD signaling. The elucidation of these genes provides a roadmap in 
which genetic insults would converge on PSD signaling, impairing synaptic plasticity, 
resulting in the decreased spine density that is linked to SCZ symptoms.  Unfortunately, 
this body of work does not provide information as to how genetic risk genes converge to 
dysregulate NR function. For example, increased NRG1-ErbB4 attenuation of NR in SCZ 
tissue provides a concrete link between the activity of a risk gene products and NR 
hypofunction at the postsynaptic density. But, genetic variation in ErbB4 can realistically 
account for only a small fraction of SCZ cases. Indeed, genetic variation in ErbB4 cannot 
even explain ErbB4 hyperactivity in SCZ.  
While the studies described above have made great strides in uncovering the 
genetic risk factors and perturbed neuronal systems that ultimately result in SCZ 
symptoms, the mechanism by which genetic risk factors set in motion these perturbations 
is currently unknown. Thus, recent studies into SCZ pathology have focused on this 
question, searching for molecular correlates that can link risk genes, NR hypofunction 
and decreased spine density.  All three of these lines of evidence predict that such 
correlates should exist, but concrete observations have proven elusive.  The next section 
discusses this conundrum in more detail.   
5. Molecular correlates of genetic risk and reduced spine density are elusive    
The loss of neuropil in the DLPFC of SCZ, specifically decreased dendritic spine 
density, may predict alterations in pre- and post-synaptic microdomains and a paralleled 
decrease in PSD proteins.  Likewise, a likely point of convergence for genetic risk factors 
to exert their effect on NR function and synaptic plasticity is through altered PSD protein 
composition and/or interactions72, 75, 78, 88.  Thus, based on this evidence, one might 
predict that synaptic protein levels would be decreased in the DLPFC of SCZ subjects, 
while the protein composition, interactions and/or posttranslational modifications of PSD 
proteins would be altered.  
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Several research groups, including ours, have investigated the transcription and/or 
translation of synaptic genes in the prefrontal cortex using a variety of techniques, 
including real time PCR, in situ and Western blot, and micro array. Despite this intense 
scrutiny, no consensus has emerged as to the existence or direction of changes in synaptic 
protein expressions levels between disease and control tissues (Note, the term expression 
is used here, and throughout the text, interchangeably with level and amount and is not 
meant to imply that transcription is the sole determiner of mRNA or protein amounts in a 
cell). Presynaptic mRNAs were once widely believed to be decreased in the DLPFC of 
SCZ subjects95, although a recent review of studies from the last decade shows that 
altered expression of presynaptic mRNAs and proteins has not been consistently 
observed 96. As for PSD protein and mRNA expression, Table 1-1 reviews the findings of 
some of the most recent studies investigating PSD95, NR1, NR2A and NR2B mRNA and 
protein levels in the PFC of SCZ patients97-105. This table highlights the lack of 
consistency in mRNA findings, as measured by in-situ hybridization and real-time PCR 
(qPCR), with most studies 
finding either a decrease or 
no change in transcriptions. 
Western blot (WB) 
investigations report more 
consistent results, with all 
but one study finding no 
difference in protein levels 
for PSD95 and NR 
subunits. Decreased spine 
density however, suggests 
that total amounts of both 
pre- and postsynaptic- 
proteins should be 
decreased in the DLPFC of 
SCZ subjects.    
Table 1-1.  Translation and transcription of PSD95 and 
NMDA receptor subunits have been repeatedly measured in 
the PFC of schizophrenia by several methods. This table 
summarizes some of the more prominent studies from the last 
15 years. Technique: Tech.: Technique used, WB: Western 
Blot, IS: in situ hybridization, RT-PCR: Real Time PCR. 
Area: the brain area used as reported in the manuscript:  FC: 
Frontal cortex, PFC: Prefrontal cortex, DL-PFC: 
Dorsolateral prefrontal cortex, BA 9: Brodmann Area 9. ?: 
No change ?: Increase ?: Decrease. 97-105  
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There are two main reasons that likely contribute to these conflicting and 
inconsistent results: 1) mRNA and protein levels could be differentially regulated. 
The largest discrepancy in the literature is the difference between mRNA and proteins 
levels. Differences in the regulation of transcription and translation as well as degradation 
of mRNA and proteins are prime candidates to explain these differences. Currently, 
technologies for quantifying mRNA are superior to those for protein in terms of 
multiplexing, accuracy and throughput. However, mRNA amounts may not reflect 
protein amounts. 2) Lack of spatial resolution.  One advantage histological studies have 
over expression technologies such as real-time PCR and Western blot, is the ability to 
resolve the unit being quantified, e.g. spines, in space. The ability to differentiate between 
cortical layers, neuronal subtypes and synaptic compartments (e.g. pyramidal neuron vs 
inter neuron and spine vs axon terminal) was essential to the successful investigation of 
total neuron number, pyramidal cell volume, dendritic branching and spine density.  
Thus, the signals of differences in mRNA or protein amount between SCZ and control 
tissues that are localized to a specific layer, neuronal type or synaptic compartment could 
be lost in the noise of a homogenized tissue sample. The introduction of laser-capture and 
linear amplification strategies have mitigated this issue somewhat, allowing for 
quantification of mRNAs in discreet cortical layers and specific neuronal populations106-
108. Laser-capture – mRNA quantification strategies, however, are still unable to asses 
protein amount, partitioning or post-translational modifications.  
Considering that the observation of decreased dendritic spines was made in 
specific cortical layers and on/about a discreet part of the neuron, the synapse, it is not 
surprising that investigations with current strategies have observed either no difference 
between SCZ or control or small inconsistent findings. Thus, there is a need to overcome 
the technical challenges described above, as identifying the molecular correlates of 
decreased spine density is likely essential for linking genetic risk to NR hypofunction. 
The observation of these correlates requires an approach with advancements over 
traditional strategies that allows for multiplex quantification of synaptic proteins, with 
high precision and accuracy and spatial resolution for synaptic microdomains, cortical 
layers and neuronal subtypes.  
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Several groups have turned to some combination of subcellular fractionation, 
immunoprecipitation and/or mass spectrometry (MS) based proteomics to qualify and 
quantify synaptic microdomain and receptor complex proteomes in animal tissues109-111. 
Unfortunately, MS proteomic strategies as currently configured are ill suited for 
addressing this specific question in human tissues. In the next section I provide a brief 
review of the more popular quantitative MS proteomics strategies and propose a more 
targeted approach to overcome some of the technical hurdles described above.  
6. Proteomics strategies in neuroscience   
Mass spectrometry (MS) based proteomics has been used extensively to catalog 
protein expression in neuronal systems109-115, 160, but application to the study of human 
disease has been limited116, 117. Technical hurdles have precluded quantitative proteomics 
investigations of synaptic microdomains, fine brain areas and discrete cell types in patient 
populations as sensitive and high-throughput proteomics methods have lagged behind 
technologies for assaying DNA and RNA. The last two decades have witnessed an 
explosion of sequencing, expression array and RT-PCR technologies, allowing for the 
routine and timely analysis of thousands of transcripts.  The addition of linear 
amplification strategies118, 119 has allowed these techniques to be applied to selected 
neuronal or even sub-neuronal populations.  Thus, expression analyses in brain tissues, 
discrete layers, and even selected populations are now routinely performed on tens to 
hundreds of clinical samples. Proteomics methodologies, while useful for identifying 
thousands of proteins in an abundant sample, have been ill suited for the types of analyses 
now routinely performed on genetic materials. 
6.1 Multi-dimensional protein identification technologies 
MS approaches to protein analysis vary, but most workflows share four concepts 
features. 1) Enzymatic cleavage of proteins into predictable peptide components. 2) 
Separation of proteins and/or peptides to overcome dynamic range differences in 
expression. 3) MS assessment of abundant peptide ions followed by isolation, 
fragmentation and assessment of peptide fragment ions. 4) Informatics analysis of these 
data matching MS spectra to predicted peptide products in a database, culminating with 
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the identification of proteins present in the sample. This strategy is often referred to as 
Multi-Dimensional Protein Identification Technology (MudPIT)120. Used in this way, MS 
based proteomics represents an unparalleled tool for the identification of proteins and 
posttranslational modifications (PTMs).   
 Quantification of these peptide fragments can serve as a quantitative measure of 
protein amount. Two popular strategies of quantification in MudPIT are Stable Isotope 
Labeling In Cell Culture (SILAC)121122 and isobaric labeling techniques such as isobaric 
Tags for Relative and Absolute Quantitation (iTRAQ)109, 123, 124.  SILAC has been widely 
employed for in vitro studies.  The cell type to be studied is grown in media in which the 
only source of the amino acids (AA) lysine (K) and leucine (L) are labeled with stable 
13C and/or 15N. After several passages, the cells will have fully incorporated the labeled 
AA and the resulting “heavy” proteome serves as an internal standard122.  
In iTRAQ the digested peptide products are chemically labeled with isobaric 
agents. The different isobaric tags will produce fragment ions with different mass to 
charge m/z ratios that can be used as a quantitative measure of the tagged peptide. 
Proteomes prepared from different samples can be tagged, pooled and analyzed together.  
This method has the advantage of allowing for multiplexed samples analysis.  Currently 
up to eight proteomes can be multiplexed. This strategy also allows for protein 
quantification in which a SILAC standard cannot be generated. However, isobaric 
labeling strategies are predicated on the assumption that chemical labeling is both 
complete and consistent, which may not always be the case. Additionally, concerns have 
recently been raised that multiple tagged peptide sequences may contribute to the 
quantitative signal assigned to a single peptide identification, confounding fidelity of 
protein quantification 125. An additional round of fragmentation may be required to 
address this issue, which could decrease the number of proteins quantified and further 
complicate an already involved bioinformatics process.   
6.2 Limitations of current strategies  
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The main drawback to both 
these strategies is the heroic 
separations efforts necessary 
to overcome the large 
dynamic range of protein 
expression. Abundant 
proteins can confound the 
observation and 
quantification of less 
abundant species in several 
ways.  Ion trap 
instrumentation widely used 
for these types of 
experiments is limited in both 
the number of ions it can 
hold and sequence (and thus, 
quantify) in a given time. 
More abundant peptides will 
be sequenced first at the 
expense of less abundant 
species. Thus deep analysis 
of a proteome requires 
fractionating the sample as 
much as possible. In practice 
this results in two dimension of separation. The first dimension is often strong cation 
exchange or hydrophilic interaction chromatography to separate peptides or 1D gel 
electrophoresis to separate proteins, both resulting in tens of fractions. These fractions are 
then separated in a second dimension, often reverse phase chromatography, over 
gradients of one to two hours. Thus, in the absence of multiplexing, the time requirement 
Figure 1-3. Selected reaction monitoring (SRM). A, 
depicts triple quadrupole MS selecting for “light” version 
of the peptide LIEDNEYTAR.  In the first quadrupole 
(Q1) the mass-to-charge ratio (m/z) of the peptide (612.3) 
is selected for, conveying it the second quadrupole (Q2) 
while discarding other ions (filtered out by m/z). In the Q2 
the peptide ion collides with an inert gas, often argon, and 
fragments into smaller polypeptides, which are conveyed 
to the third and final quadrupole (Q3). Here an m/z, 
corresponding with a known fragment ion (997.4), is 
selected to move onto the detector, while all other m/z’s 
are discarded. B. Depicts the same operation performed on 
“heavy” (stable isotope labeled) LIEDNEYTAR. C. 
Chromatograms resulting from the selected monitoring of 
the “light” and “heavy” species of LIEDNEYTAR when 
the SRM is coupled with liquid chromatography. 
Calculating the area under the curve for each peak, and 
utilizing the “heavy” peptide as a standard facilitates 
relative or absolute quantification of the selected peptide in 
a complex biological matrix.  
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for analysis of a single sample can approach twenty-four hours. Additionally, MudPIT 
has relatively high protein requirements, which is problematic if the goal is to assay 
protein composition of microdomain enrichments, neuronal layers or discreet neuronal 
populations.  In the limited number of quantitative proteomics studies performed on 
human brain tissue to date, the time and protein requirements have often necessitated 
subject pooling, severely limiting statistical power and eliminating the ability to observed 
protein patterns of individuals.  Clearly, if quantitative proteomics is to meet the 
challenges described at the end of section 5, a new strategy is required.   
6.3 Selected reaction monitoring, a more selective approach 
Selected reaction monitoring (SRM) is a MS methodology routinely used for the 
quantification for specific ions in a complex sample matrix126-128. As opposed to the 
quantitative MudPIT strategies described above, SRM is usually performed on a triple 
stage quadrupole (QqQ) MS instrument.  When configured for peptide quantification, the 
first quadrupole selects for the m/z of the peptide conveying it the second quadrupole 
while discarding other m/z’s. In the second quadrupole the peptide ion collides with an 
inert gas, often argon, and fragments into smaller polypeptides ions, which are conveyed 
to the third and final quadrupole. Here an m/z, corresponding with a known fragment ion, 
is selected to move onto a detector, while all other m/z’s are discarded (Figure 1-3). 
Coupled with high performance liquid chromatography (HPLC), the filtering for two 
m/z’s specific to a target peptide SRMs on QqQ instruments can monitor the intensity of 
a that peptide in a highly complex biological matrix. The addition of a stable isotope 
labeled internal standard facilities accurate quantification128. State of the art QqQ 
instruments can perform this operation up to 200 times in a second while maintaining 
sensitivity in the attomole range. Additionally, SRMs can be timed to correspond with 
peptide elution in HPLC. Thus with a priori knowledge SRM strategies can facilitate the 
quantification of hundreds of target peptides in a complex matrix. The development and 
application of this type of approach is described in detail in Chapter 3.  
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7. Summary and Research Scope 
Multiple lines of evidence implicate decreased spine density, perturbed 
neuroplasticity and NR hypofunction in the pathology of SCZ. NRs are localized to 
PSDs, where extra- and intra-synaptic factors converge non-linearly to regulate NR 
activity and neuroplasticity, while PSDs are located at dendritic spines. Many SCZ risk 
genes code for PSD proteins, implicating the PSD as a site of convergence at which 
genetic risk factors converge to impair plasticity over development.  
Decreased spine density in the DLPFC of SCZ subject suggest that levels of PSD 
proteins could be decreased as well, while some combination of altered PSD protein 
amount, partitioning, interactions and posttranslational modifications likely underlie NR 
hypofunction. These same molecular correlates of decreased spine density and NR 
function are believed to fingerprints of genetic risk factors. Thus, the elucidation of these 
molecular differences between SCZ and control is currently an important goal of SCZ 
research. 
Investigation of molecular alterations in postmortem brain tissue of patients has 
been hindered by the lack an approach capable of assaying large numbers of proteins, 
with high sensitivity, accuracy, precision, throughput and spatial resolution. The goal of 
this thesis work is to develop and validate an MS based method to meet some of these 
needs and utilize it to investigate PSD protein expression and partitioning in the DLPFC 
of SCZ subjects.  
The following aims were developed to address these goals and represent the scope of this 
thesis research: 
Research Aim I 
Catalog the proteins present in PSD enrichments prepared from human postmortem brain 
tissue to generate the database necessary for development of an MS method. 
Research Aim II 
Develop and validate an LC-SRM/MS method for the selective quantification of 
hundreds of targeted mammalian synaptic proteins, and utilize this method to further 
validate biochemical fractionation of human postmortem brain tissue.  
Research Aim III 
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Characterize protein expression and PSD protein composition in the lateral PFC of SCZ 
and matched control subjects. 
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CHAPTER TWO 
CHARACTERIZATION OF HUMAN POSTSYNAPTIC 
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1. Abstract  
Recent molecular genetics studies have suggested various trans-synaptic processes for 
pathophysiologic mechanisms of neuropsychiatric illnesses. Examination of pre- and 
post-synaptic scaffolds in the brains of patients would greatly aid further investigation. 
Biochemical fractionation in human postmortem tissue has yet to be tested and current 
proteomics methods used to analyze these preparations in animal models are not well 
suited for clinical applications. I performed a two-dimensional liquid chromatography-
tandem mass spectrometry (2D LC-MS/MS) analysis of human PSD fractions, prepared 
with a protocol validated by Western blot (WB) and electron microscopy (EM).  This 
study represents the first analysis of PSD enrichments from human tissue.  Over 1800 
proteins were observed and were striking similar to data sets generated by similar 
analyses of rodent tissues. These results demonstrate that PSD fractions isolated from 
human postmortem brain tissues are assayable by MS proteomics, and lay the foundation 
for development of a targeted quantitative method.  
2. Introduction  
Recent studies in neuropsychiatric illnesses have implicated various trans-synaptic 
mechanisms72, 74, 75, for which protein compositions in sub-cellular microdomains are 
crucial44, 59, 129, 130 [8-12]. The postsytnaptic density (PSD) is a particularly interesting 
microdomain since multiple candidate genes for psychoses and mood disorders converge 
on their signaling mechanisms72, 74, 7577.  Thus, the ability to isolate these domains and 
quantify the proteins there in will greatly aid our understanding of neuropsychiatric 
illnesses.  We, and others, have recently applied similar approaches to human 
postmortem brains 131, 132, but the feasibility and validity have not been fully elucidated. 
Additionally, while the MS proteomics strategies described in Chapter 1 have been 
extensively utilized for microdomains derived from rodent brains109, 133, 134 [14-17], they 
are ill suited for clinical studies as throughput is limited.  A targeted approach with 
greater throughput and sensitivity is required111. The design of this type of method first 
requires a qualitative analysis of the target proteome, which has not been performed in 
microdomains prepared from human postmortem brain tissue. In this study, the protein 
composition of biochemical fractions enriched in the PSD of human postmortem brains is 
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evaluated by two-dimensional liquid chromatography-tandem mass spectrometry (2DLC-
MS/MS).  
The PSD is a highly organized biochemical apparatus attached to the postsynaptic 
membrane129, which can be visualized as an electron dense thickening under electron 
microscopy. The PSD contains glutamatergic receptors, N-methyl-D-aspartic acid 
(NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA), 
the group I metabotropic glutamate receptors (mGluRs) and numerous signaling 
molecules129. As a molecular scaffold, the PSD brings together various sets of signaling 
molecules and modulates their interactions and their activities.   
The PSD is relatively insoluble in non-ionic detergents and can be purified by 
differential centrifugation 135. Various protocols have been used to isolate the PSD from 
rodent brains based on a fundamental principle of: a) purification of synaptic membranes, 
b) extraction of the membranes with non-ionic detergents and c) separation of the 
resultant disk-shaped protein structures. Protocols have often differed in the degree of 
detergent extraction, thereby determining the inclusiveness of proteins in the final 
fractions. These include Triton X-100 or N-lauryl sarcosinate and the use of harsher 
detergents retrieves a more stripped down version of proteins135. Indeed, variations of 
these methods allowed separation of fractions containing synaptic vesicles and synaptic 
membranes from the PSD136, 137.  
Protein composition of protein complexes can be profiled using proteomic 
analysis. Several groups have analyzed the rodent PSD using 2D fluorescence difference 
gel electrophoresis (2D DIGE) or LC-MS/MS and identified sets of proteins, including 
known PSD proteins previously characterized by the immunoblot method111, 115. 
However, depending on the methods of fractionation and proteomics analysis, these 
studies have reported variable numbers of proteins in PSD enrichments, ranging from a 
few hundred to more than a thousand. Posttranslational modifications (PTM) appear to be 
maintained through the rigorous biochemical fractionation procedure, and groups have 
identified phosphorylation sites on PSD proteins109, 134, 138, 139. Biochemical fractionation 
of postmortem brain tissues faces special challenges due to various confounding factors 
inherent to these tissues140, 140. They include prolonged agonal state, complicating 
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medical conditions, the post-mortem interval (PMI), inconsistent pH, and duration of 
storage and temperature of the tissues.  These conditions are thought to disrupt the 
integrity of proteins, ultrastructures or microdomains141-143. Therefore, few attempts have 
been made to isolate the PSD or other sub-cellular fractions from human postmortem 
brains [37].  In the present study, we have isolated PSD fractions from human 
postmortem brain tissues, verified the enrichment, protein composition, and integrity of 
ultrastructures using Western blot, electron microscopy and performed qualitative 
proteomic analysis. 
3. Materials and Methods 
3.1  Human tissues:  
Tissue samples were dissected from the prefrontal cortex (Brodmann area 9) of 
two healthy control human brain samples in order to provide sufficient confidence in 
protein identifications.  Consent for tissue collection was granted prospectively by 
patients and autopsy consent granted by the next-of-kin at time of death.  The 
postmortem enrollment was conducted under Conte Core A, IRB number 703835 and 
postmortem protocol was conducted under IRB number 188200. 
3.2 Biochemical fractionation:  
300-350 mg of frozen postmortem brain tissue was dissected and homogenized in 
1.5ml of solution A (0.1mM CaCl2, 1mM MgCl2 and 0.32M sucrose) supplemented with 
protease and phosphatase inhibitor cocktails (Sigma). This homogenate was adjusted to 
1.25M Sucrose and 0.1mM CaCl2 to a total volume of 5ml. 5ml of 1M sucrose was 
overlaid on this and ultracentrifuged at 28000 rpm (100,000×g) for 3 hrs in a SW 40 Ti 
rotor using a Beckmann L7 Ultracentrifuge. The band at the interface of 1.25 and 1 was 
collected with a needle as SPM.  The SPM was diluted with 5X 0.1mM CaCl2 and 
centrifuged at 12000rpm (15000×g) for 20 minutes.  
For PSD preparation, a 500μl aliquot of SPM was diluted with ice cold 0.1mM 
CaCl2 to 2.5ml, followed by the addition of 2.5ml of 40 mM Tris-HCl pH 6 
supplemented with 2% Triton-X 100 and protease and phosphatase inhibitors, bringing 
the final volume to 5ml with 20mM Tris and 1% Triton-X 100.  The samples were left in 
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cold room rocker for 30 minutes and centrifuged at 18000 rpm (35,000×g) for 20 
minutes.  The supernatant, designated as the vesicular fraction (SV), was then diluted 
with 5X chilled acetone and left in -20°C overnight.  The pellet was air dried and 
dissolved in 1 ml CaCl2, then 1 ml 40mM Tris pH 8 with 2% Triton-X 100 , was added 
for the final concentration of 20mM Tris and 1% Triton-X. The sample was left on a 
rocker for 60 minutes and centrifuged at 36000 rpm (140,000×g) for 30 minutes. The 
supernatant, designated as the parasynaptic membrane fraction was acetone precipitated 
at -20°C overnight. The pelleted PSD was air dried and dissolved in 20mM Tris pH 7.4. 
Acetone precipitated SV and PPF fractions were centrifuged at 15000 rpm (24,000×g) for 
30 minutes and pellets were dissolved in 500μl of 20mM Tris pH 7.4 with triple 
detergent. 
3.3 Western Blotting: 
The samples were transferred on PVDF membrane (Millipore) and probed with 
the following antibodies: mouse monoclonal PSD-95, 1:1000 (Upstate or NeuroMab, UC 
Davis, CA), rabbit polyclonal pS295-PSD-95 1:250 (Abcam), mouse monoclonal 
synaptophysin 1:5000 (Chemicon), mouse monoclonal β-actin 1:5000 (Sigma), rabbit 
polyclonal ErbB4, goat polyclonal NR1, goat polyclonal NR2A (Santa Cruz) , NR2B 
1:1000 (a gift from Dr. Barry Wolfe, Georgetown University Medical Center, 
Washington, DC 20057, USA), rabbit polyclonal vGlut1 (Synaptic System), mouse 
monoclonal Munc18 and RAB3 (BD Biosciences). The blots were developed using 
chemiluminescent reagents ECL or ECL-Plus, or a combination of both (GE Healthcare). 
400 µgs of SF or 10 µg of PSD from the same subject were immunoprecipitated after 2 
hours preclearing with Protein A agarose with 6 µg of goat polyclonal NR1 antibody 
(Santa Cruz) in immunoprecipitation buffer (25 mM Tris-HCl, pH 7.4, 200 mM NaCl, 2 
mM EDTA, 0.5 mM EGTA supplemented with protease and phosphatase inhibitors from 
Sigma) at 4°C overnight. The samples were incubated with 25 µl of Protein A agarose 
Plus (Pierce) for 2 hrs at RT. The immunoprecipitated samples were separated on a 7.5% 
SDS precast gel (Biorad) and probed with mouse monoclonal PSD-95, 1:1000 
(NeuroMab), Goat Polyclonal NR1 and NR2A 1:500 and mouse monoclonal PLCγ1 
1:250 (Santa Cruz). 
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3.4 Electron Microscopy: 
Pellets were fixed in 2.5% 
glutaraldehyde/2% 
paraformaldehyde, embedded in 
epon, and post-stained with urayl 
acetate and bismuth subnitrite.  
Ultrastructural examination was 
performed with a JEOL JEM -1010 
electron microscope. Images were 
captured with a Hamamatsu CCD 
ORCA digital camera, using AMT 
Advantage software version 
5.4.2.308 (Advanced Microscopy 
Techniques). 
3.5 Multidimensional 
fractionation-tandem mass 
spectrometry: 
PSD fractions were 
prepared and purity confirmed by 
western blot analysis of PDZ 
domain and synaptophysin (Figure 
2-1).  Each pellet was washed 3 
times with 20mM Tris pH 7.4 at 
4°C and suspended in 25mM ammonium bicarbonate with 6M guanidine hydrochloride.  
Protein concentration was determined by Coomassie Plus reagent (Promega, Madison, 
WI) with a BSA standard curve read at 595nm on an EL808 Microplate Absorbance 
Reader (BioTek, Winooski, VT.  Two enrichments per biological sample were pooled to 
give 600 µg PSD protein.  2D LC-MS/MS was performed using a variation of the method 
described by Trinidad et al. 109.  Cysteine side chains were reduced and alkylated by 
incubation with 5mM dithiothreitol (DTT) for 45 min at 60°C and 15mM iodoacetamide 
Figure 2-1. Subcellular fractions were analyzed by 
WB. Abbreviations: T: total tissue extracts, C: 
cytosolic extracts, S: SPM, synaptosomal membrane, 
V: SV, vesicular fraction, P: PPF: presynaptic 
fraction, D′: PSD isolated by the method 1, ’: D:PSD 
isolated by the method 3. NR: NMDA receptor, 
Synph: synaptophysin, vGlut1: vesicular glutamate 
reuptake site.  
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for 45 min at room temperature in the dark.  The mixture was diluted to a final 
concentration of 1M guanidine with 25mM ammonium bicarbonate and 75µg modified 
trypsin (Promega, Madison, WI).  The mixture was adjusted to a pH of 8.0 and incubated 
for 12 hrs at 37°C.  Digests were desalted with a Peptide Macrotrap Cartridge 
(MICHROM Bioresources, Inc, Auburn, CA) and lyophilized to ∼5 µl.  Peptides were re-
suspended in 100µl strong cation exchange (SCX) buffer A (30% acetonitrile, 5mM 
KH2PO4, pH 2.7).  SCX was performed on the entire sample using an Agilent 1100 series 
HPLC with Chem Station for LC (Agilent Technologies, Santa Clara, CA) using a 
PolySULFOETHYL column, 2.1mmID x 100mm, 5µ, 300Å (The Nest Group, 
Southborough, MA). SCX buffer B consisted of buffer A with 350mM KCL.  The 
gradient was held at 0% B for 9 min and then went from 0% B to 29% B over 54 min, 
29% B to 75% B over 45 min, and 75% B to 100% B over 9 min, with a flow rate of 100 
µl/min.  Fractions were collected every three minutes.  The first 5 fractions were pooled, 
giving a total of ~ 50 fractions per sample.  Fractions were lyophilized and re-suspended 
in reverse phase (RP) buffer A (0.5% acetonitrile 0.1% formic acid in H20).  One tenth of 
each individual SCX fractions was injected on a 5µl loop from a CTC pal auto-sampler 
(Leap technologies, Carrboro, NC) and peptides loaded onto Vydac Everest C18 column, 
300Å, 5µm, 100mm, 500µm ID (The Nest Group) at 20 µl/min in 100% RP buffer A 
with an Express C100 system (Eksigent Technologies, Dublin, CA).  The mobile phase 
was diverted to waste for the first 10 min to remove KCl and other salts.  The flow rate 
was then reduced to 12µl/min and peptides were eluted over a 50 min gradient from 0% 
to 40% RP buffer B (5% H20, .1% formic acid in acetonitrile).  After elution the column 
was washed for 10 min with 100% RP buffer B and equilibrated for 10 min with 100% 
RP buffer A.  The LTQ mass spectrometer (ThermoFisher Scientific, San Jose, CA) was 
operated in the positive ion mode using electrospray ionization with a capillary 
temperature of 200°C.  Nitrogen was used as a sheath gas at 41 and an auxiliary gas at 12 
(arbitrary units).  MS spectra were acquired for a mass range of 400 – 1200 m/z over 30 
milliseconds.  The top 5 most intense ions per spectra were selected and sequenced with a 
collision induced dissociation energy (CID) of 35.0 and activation energy of 25 (arbitrary 
31 
 
units).  A dynamic exclusion window was applied to prevent the selected ions from being 
sequenced for 200 ms after the initial acquisition.   
3.6 Peptide and protein identification and scoring  
The data sets were searched against the International Protein Index (IPI) human 
protein sequence database (version 3.43, number of protein sequences: 72,346, total 
length of database entries: 30,410,250 amino acid residues) for peptide sequences using 
SEQUEST 3.1 (ThermoFisher, San Jose, CA). Raw mass spectra were converted to DTA 
peak lists using BioWorks Browser 3.2 (ThermoFinnigan) with the following parameter 
settings: peptide mass range 300-5000 Da, threshold 10, precursor mass ±1.4 Da, group 
scan 1, minimum group count 1, minimum ion count 15. SEQUEST searches specified 
that peptides should have a maximum of two internal tryptic cleavage sites and possess 
two tryptic termini, with methionine oxidation and cysteine carbamidomethylation as 
possible modifications and used a peptide mass tolerance of ±1.4 Da and a fragment ion 
tolerance of 0. The search results were converted into pepXML format. Peptide 
identification probabilities were calculated by executing PeptideProphet as implemented 
in the Trans-Proteomics Pipeline version 2.8 (Institute for Systems Biology, Seattle, 
WA)144. SEQUEST results were processed using the "-Ol" tag, which uses ΔCn* values 
unchanged. 
Results from both biological replicates were combined in a single statistical 
analysis of protein expression using the EBP 1.0 as described previously145. Briefly, EBP 
estimates both sensitivity and false identification rate and has been validated empirically 
for LTQ ion trap data using a reversed/forward sequence database search approach145. 
EBP combines the probabilities of correct peptide identification across multiple peptide 
searches using a function that returns the maximum probability from consensus 
identifications, and penalizes non-consensual identifications. Replicates are integrated by 
simultaneously estimating multiple sets of model parameters. Peptides whose sequence 
matches multiple proteins are integrated in the analysis using "Occam's Razor", a 
principle by which the smallest set of probable proteins that is sufficient to explain the 
peptide sequence identifications is chosen. When proteins cannot be reliably 
distinguished by unique peptides, they are reported as a protein group. Only proteins with 
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expression probabilities corresponding to a false identification rate of less than 0.01 (1%) 
were reported (1863 proteins). This was equivalent to expression probabilities of p > 0.90 
in this data set. One hundred thirty two additional proteins with p > 0.90 were members 
of groups of similar proteins, which could not be distinguished based on the peptide 
evidence.  A separate analysis utilizing a forward/reversed database yielded near identical 
protein identifications at a 1% false positive cut off (data not shown).   
MS/MS spectra of at least two peptides each from 63 PSD proteins (Sup. Table 2-
1)  were validated by comparison with product ions estimated from ProteinProspector 
(v4.27.2, http://169.230.19.26:8080/).  Peptides from select proteins (Sup. Table 2-1) 
were subjected to targeted MS/MS analysis to further confirm peptide and protein 
identifications.  These addition spectra were not included in LC-MS/MS data analysis 
statistics.   
3.7 Comparison of PSD proteins with previous datasets: 
Orthologous sequences for proteins identified in rat and mouse PSD enrichments 
from Dosemeci et al. and Trinidad et al., respectively, and our human data set were 
derived from the Mouse and Rat Genome Database (MGD, 
http://www.informatics.jax.org/).  In our data set we saw evidence for 5338 unique IPI 
protein accessions collected into 2728 protein groups, where each member of a group was 
indistinguishable from the other, usually different isoforms of a single protein, based on 
observed peptides.  IPI identifiers were assigned to these using the cross-reference 
information for each entry.  These sequences were compared by analyzing the sequence 
homology between them using BLAST 41. The search was performed using the 
BLOSUM62 matrix, with gap and extension penalties of 11 and 2, respectively and with 
a sequence homology cutoff of 90%. 
4. Results 
4.1 EM and Western Blot analysis of PSD fractions  
The integrity of isolated fractions was tested using EM. Figure 2-2A and B show 
a thin section electron micrograph of SPM and demonstrate strikingly intact synaptsomes 
that contain synaptic vesicles and filamentous connections to other synaptosomes. Figure 
2-2C represents soluble fraction of pH 6 TritonX-100 extraction and shows paired pieces 
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of electron dense membranes. The more electron dense membrane is thought to be 
postsynaptic. Figure 2-2D shows that PSD fraction is largely devoid of the fine 
substructures of synaptic junctions.  
 The relative purity of these fractions was examined by immunoblotting analysis.  
Figure 2-1 shows that PSD proteins, NMDAR1, NMDAR2, Homer and PSD-95, were 
enriched in the PSD fractions, while these proteins are much less represented in the 
vesicular or parasynaptic fractions. In contrast, presynaptic proteins, Rab3, NRG1, 
synaptophorin, vGAT, vGlut1, were mostly enriched in fraction vesicular but not in the 
PSD fraction. 
4.2 Protein identification 
Two biological samples 
of PSD fractions, enriched by 
Method 2, were analyzed by 2D 
LC-MS/MS.  Peptide 
identifications were assigned 
by SEQUEST (ThermoFisher) 
and peptide and protein 
probabilities determined by 
Empirical Bayes Protein 
Identifier (EBP).  At a 1% false 
positive threshold 1863 
nonredundant proteins or 
protein groups were identified. 
A separate analysis utilizing a 
reverse database yielded near 
identical protein identifications 
at a 1% false positive cut off 
(data not shown).  
Inspection of the 
Figure 2-2. (A, B) Thin sections of SPM pellets show 
surprisingly intact synaptosomes and intact synaptic 
vesicles (A, B) as well as filamentous crossbridges (see 
arrows in B). (C) Synaptic membrane fractions extracted 
by Triton-X 100 at pH 6.0 show paired electron dense 
profiles representing synaptic junctions (see arrows in C). 
(D) PSD fraction obtained as an insoluble phase after 
synaptic membranes were extracted with Triton-X 100 at 
pH 8.0. Note that presynaptic specialization is removed 
and that the PSD is thinner than shown in A and B.  
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identifications revealed proteins with well-theorized functions in the PSD, as identified 
by review of recent literature109, 146, such as the Discs Large Homologs (IPI00552511, 
IPI00647950 & IPI00790650), Homer (IPI00003566), SHANK (IPI00019794), G 
proteins (e.g. IPI00290928), glutamate receptors (e.g. IPI00297933), and various kinases 
(e.g. IPI00007128) and phosphatases (e.g. IPI00008380).  Peptides from 36 consensus 
PSD proteins, as identified in Collins et al. 147, were selected and confirmed by spectra 
inspection and/or targeted MS2 analysis of peptide ions.  The complete data set can be 
viewed at Peptide Atlas, sample IDs 040804_HumanBrain and 052104_HumanBrain.  
For a complete list of proteins and protein groups see: Supplemental Table 2-2 (Appendix 
2) or http://spreadsheets.google.com/pub?key=pDgU17zRNrsAy-GrFicBkLQ 
4.3 Grouping of protein identifications  
To gain a broader view of these data, protein identifications were grouped by 
cellular compartment, biological process and molecular function using gene ontology 
(GO) annotations where available (Supplemental Figure 2-1A, B & C).  While many 
proteins segregated to biological processes and molecular functions associated with the 
PSD, such as localization, stimuli response, molecular transduction, structural, and 
regulators of enzymatic activity, a large number of the proteins were found to be involved 
in processes not associated with the PSD most notably metabolism and gene expression.  
These types of contaminants have routinely been observed in similar analyses PSDs 
prepared from rodents.  While it is possible that these identifications represent proteins 
with hitherto unknown function in the microdomain, they are much more likely 
contaminants from the biochemical fractionation, the result of either close association 
with the PSD microdomain (presynaptic proteins) or common biopsychical properties 
(mitochondrial membranes).  
4.4 Comparison to similar analyses of rodent PSDs 
We sought to further validate our findings by comparing our data set to those 
from previous LC-MS/MS analyses of mammalian PSD enrichments.  To that end we 
compared our protein identifications to those obtained from mouse brain PSD 
enrichments148and an IP of the PSD-95 protein complex from rat brain PSD enrichments 
149.  Close to 800 proteins were shared between the Trinidad dataset and our own when 
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compared by sequence homology of >90% including PSD proteins and likely 
contaminants such as mitochondrial, ribosomal and pre-synaptic (Data not shown).  
Additionally, when compared by sequence homology 28 of the 62 proteins listed in 
Supplemental Table 2-1 were found in one or both of the rodent sets.  To reduce the 
impact of sequence variation between species, the proteins reported in Supplemental 
Table 2-1 were compared to the rodent data sets by IPI identifier.  In this analysis, all but 
10 of the 63 theorized proteins we found were present in one or both of the rodent data 
sets.  
5. Discussion  
2D LC-MS/MS was employed to characterize the protein composition of PSD 
fractions. PSD enrichments from two biological samples were combined in a statistical 
analysis, which integrates data from consensual and non-consensual peptide 
identifications in a Bayesian fashion145. Our list of identified proteins appears highly 
inclusive, yet provides an extensive coverage of known PSD proteins, as evidenced by 
the proteins cataloged in Supplemental Table 2-1. The number of proteins in the PSD is 
presently unknown 146. Using immuno-EM, EM tomography, and scanning transmission 
EM, Chen et al (2005) and Petersen et al (2003) have estimated that an average PSD with 
a 360 nm diameter and a total molecular mass of 1.10±0.36 gigadaltons, could be 
composed of 10,000 proteins of 100kD150, 151.  
Proteomic analyses are prone to detecting contaminants that are either highly 
abundant in target tissues or co-enriched during biochemical fractionation 146. Indeed, this 
list high highly comparable to an analysis of mouse PSDs that utilized a similar 2DLC-
MS/MS strategy in terms of both confirmed PSD proteins and suspected contaminants.  
The next step is to determine which of these proteins are specific to the PSD or highly 
enriched in this microdomain compared to others and total homogenates.  
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1. Abstract  
Synaptic architecture and its adaptive changes require numerous molecular events 
that are both highly ordered and complex. A majority of neuropsychiatric illnesses are 
complex trait disorders, in which multiple etiologic factors converge at the synapse via 
many signaling pathways. Investigating the protein composition of synaptic 
microdomains from human patient brain tissues will yield valuable insights into the 
interactions of risk genes in many disorders. These types of studies in postmortem tissues 
have been limited by the lack of proper study paradigms. Thus, it is necessary not only to 
develop strategies to quantify protein and posttranslational modifications at the synapse, 
but also to rigorously validate them for use in postmortem human brain tissues.  In this 
study we describe the development of a liquid chromatography-selected reaction 
monitoring method, utilizing a stable isotope-labeled neuronal proteome standard 
prepared from the brain tissue of a stable isotope-labeled mouse, for the multiplexed 
quantification of target synaptic proteins in mammalian samples. Additionally, we report 
the use of this method to validate a biochemical approach for the preparation of synaptic 
microdomain enrichments from human postmortem prefrontal cortex.  Our data 
demonstrate that a targeted mass spectrometry approach with a true neuronal proteome 
standard facilitates accurate and precise quantification of over 100 synaptic proteins in 
mammalian samples, with the potential to quantify over 1000 proteins. Utilizing this 
method, we found that protein enrichments in subcellular fractions prepared from human 
postmortem brain tissue were strikingly similar to those prepared from fresh mouse brain 
tissue. These findings demonstrate that biochemical fractionation methods paired with 
targeted proteomic strategies can be utilized in human brain tissues, with important 
implications for the study of neuropsychiatric disease. 
2. Introduction 
Synaptic architecture and its adaptive changes require numerous molecular events 
that are both highly ordered and complex60, 152. Molecular and cellular research into these 
processes has, until recently, been limited to technologies that can examine one molecule 
to the next within a cascade.  In the last decade, mass spectrometry (MS)-based 
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proteomic methodologies, paired with biochemical fractionation techniques, have enabled 
us to begin cataloging the proteomes and signaling of mammalian synaptic 
microdomains60, 111, 153-155 and microdomain specific protein complexes114, 133, 156. These 
studies have revealed that synaptic architecture and plasticity involve numerous 
interactions between multiple signaling mechanisms with robust crosstalk and protein 
interactions114 133 86 109. These findings also dovetail with decades of genetic studies into 
neuropsychiatric disease, which have identified dozens of risk genes spread across 
multiple pathways at the synapse157, 158.  Historically, signaling cascades and molecular 
disease models have been depicted as a string of molecular events that are connected in 
tandem.  Such views were shaped in part by the methodologies that permitted the 
measure of a handful of protein events at a time.  MS-based proteomic methodologies can 
monitor numerous proteins and posttranslational modifications simultaneously, 
permitting us to examine signaling pathways in the context of many other intracellular 
molecular events.  The next challenges in the field of neuroscience will be to establish 
methodologies for quantitative assessment of proteomes in specific microdomains of 
neural tissues, to monitor these numerous molecular events simultaneously, and to 
understand them within the context of nonlinear intracellular trafficking, protein 
interactions and posttranslational modifications.  
Postmortem brain studies are a critical component of neuropsychiatric research as 
brain tissues of patients may harbor pathophysiologic information of the illnesses.  A 
majority of neuropsychiatric illnesses are complex trait disorders, in which multiple 
etiologic factors converge at the synapse via many signaling pathways157, 158. The 
application of advanced molecular and cellular technologies to access synaptic 
microdomains, however, has been limited in postmortem brains by confounds such as 
therapeutic intervention, agonal state, and postmortem interval.  Thus, there is a pressing 
need to validate and focus these biochemical fractionation and MS proteomic methods for 
use with human postmortem brain tissue.  The vast majority of previous neuroproteomic 
studies have employed two dimensional separation/tandem MS approaches to perform 
qualitative analyses of mammalian synaptic preparations133, 153, 155. Protein quantification 
has been accomplished utilizing either synthetic stable isotope-labeled peptide 
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standards111 or isobaric peptide labeling methods, such as iTRAQ109, 123.  Sample workup 
can complicate the application of isobaric tagging in an efficient and reproducible 
manner159, while synthetic peptide standards are costly and have difficulty controlling for 
confounds in sample preparation, most notably protein digestion160. Stable Isotope 
Labeling by Amino acids in Cell culture (SILAC) can produce only a partially labeled 
neural proteome161 and we have found that full expression levels and synaptic 
architecture of brain tissue are difficult to reproduce in fully labeled cultures. The recent 
availability of Stable Isotope Labeling in Mammals (SILAM) mouse tissue allows for the 
generation of a stable isotope labeled neuroproteome within the context of native tissues 
to serve as an internal standard for the quantification of a vast number of proteins162. 
Walther et al. recently utilized SILAM tissue to quantify over 4000 proteins in mouse 
hippocampus and cortex163.  Considering the high level of homology between 
mammalian neuronal transcripts75, we investigated the suitability of this stable isotope-
labeled proteome to serve as a protein standard for human tissue as well as additional 
model organisms. 
In this study we first describe the development and validation of liquid 
chromatography-selected reaction monitoring (LC-SRM)/MS-based methodology for 
studies of mammalian synapses.  Quantification of 189 neuronal proteins was conducted 
utilizing a [13C6] lysine-labeled brain proteome internal standard ([13C6] brain ISTD) 
prepared from [13C6]lysine SILAM mouse brain tissue.  We also report the application of 
this method to further validate biochemical fractionation of human postmortem brain 
tissue for the study of synaptic biology in human disease.  We observed highly 
reproducible enrichment of proteins into synaptic microdomains in a function- and 
family-specific manner.  These protein enrichments were remarkably comparable 
between fresh-frozen mouse and human postmortem tissues.  Additionally, bioinformatic 
analyses indicate that this method has the capability to quantify thousands of additional 
neuronal proteins in many model systems.  These experiments demonstrate that the 
biochemical fractionation coupled with LC-SRM/MS and [13C6] brain ISTDs provides a 
powerful tool for investigating the protein composition of synaptic microdomains in 
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mammalian tissues, with broad application to neuropathology and neurological studies in 
humans and model systems. 
3. Materials and Methods 
3.1  Brain tissues:   
Prefrontal cortex (Figure 3-1B) tissue slices from three cognitively and 
neurpathologically normal subjects without were obtained from the University of 
Pennsylvania (UPenn) Brain Bank.  Consent for tissue collection was granted 
prospectively by patients.  Autopsy consent was granted by the next-of-kin at time of 
death. Postmortem enrollment, brain autopsy, and neuropathological assessment were 
conducted under UPenn Conte Core A, IRB numbers 703835 and 188200. After death, 
the cases were stored at 2-4°C until transport to UPenn, where all autopsies were 
performed. Upon sagittal bisection, a hemispheres from each case was cut into coronal 
slabs, which were frozen overnight at -80°C and then sealed in plastic bags for long-term 
storage at -80°C. Tissue samples from the other hemisphere were fixed and prepared for 
microscopic analysis. The cases were examined by trained neuropathologists for gross 
and microscopic abnormalities diagnostic of diverse neurodegenerative dementias.  We 
selected fresh frozen tissue from the prefrontal cortex because its large volume allowed 
repeated sampling without depleting resources available for other studies on precious 
normal human brain tissue.    Within this restriction, we selected tissues with a wide 
range in age, sex, and postmortem interval (PMI) (Figure 3-1B).  Mouse brain tissues 
consisted of the forebrain plus midbrain olfactory bulb, were dissected from three male 
C57/BL6 mice 8-12 months old.  
3.2  Biochemical fractionation:   
Synaptic fractions were obtained using a biochemical method we previously 
validated for use in human postmortem brain tissue (Figure 3-1)153.  300-350 mg grey 
matter was homogenized in 1.5 ml solution A (0.32 M sucrose, 1mM MgCl2 and 0.1mM 
CaCl2) with a Teflon pestle.  ~100 μl of the homogenate (H) was saved, solubilized with 
1% SDS and clarified by centrifugation.  The remaining homogenate was centrifuged at 
2,500 RPM for 15 min.  The pellet was discarded and 100 μl of the supernatant agitated 
on a rocker at 4°C with a final concentration of 0.5% digitonin, 0.2% sodium cholate and 
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0.5% NP-40for 1 h, centrifuged at 14,000 RPM for 20 min, and the supernatant was 
saved as the Synaptosomal fraction (SF).  The remainder of the supernatant prepared 
from the 2500 RPM spin was adjusted to 1.25 M sucrose with 2M sucrose and 1mM 
CaCl2to a final volume of 5 ml.  5 ml of 1 M sucrose was overlaid and the gradient 
ultracentrifuged at 28,000 rpm for 3 h in a SW 40 Ti rotor using a Beckmann L7 
Ultracentrifuge. The band at the interface was collected, diluted 1:10 in 0.1 mM CaCl2 
and centrifuged at 12,000 RPM for 20 min.  The supernatant was discarded and the pellet, 
the intermediate membrane fraction (IM), was dissolved in 1 ml 20 mM Tris pH 6.0 and 
sonicated with three 10-second pulses.  1 ml 20 mM Tris pH 6.0 with 2% Triton X-100 
(Sigma) was added to the solution and agitated on a rocker at 4°C for 30 min, followed 
by centrifugation at 18,000 RPM for 30 min.  The supernatant, the Vesicular fraction (V), 
was precipitated in acetone at-20°C overnight. The pellet was air dried, dissolved in 1 ml 
20 mMTris pH 8.0, sonicated with three 10-second pulses, mixed with 1 ml of 20 mM 
Tris pH 8.0 with 2% Triton X-100, agitated on a rocker at 4°C for 45min and centrifuged 
at 36,000 RPM for 1 h.  The resulting supernatant, the Parasynaptic membrane fraction 
(P), was precipitated in acetone at -20°C overnight.  The pellet, the PSD fraction (D), was 
air dried, washed three times with 20 mM Tris pH 8.0 and dissolved in 300 μl 20 mM 
Tris pH 7.4 with 1% SDS.  Following acetone precipitation, the V and P fractions were 
centrifuged at 3,000 RPM for 30 min and dissolved in 100 μl 20 mM Tris pH 7.4 with 
1% SDS.   
To prepare the [13C6] brain ISTD, 400 mg labeled MouseExpress brain tissue 
(Cambridge Isotopes, MA) was homogenized in 4 ml buffer A as described above, 
centrifuged at 1,000 x g for 10 min to clarify, agitated on a rocker at 4°C for 30 min, and 
centrifuged at 10,000 x g for 20 min.  The pellet, a crude membrane fraction, was 
dissolved in 2 ml 20 mM Tris pH 7.4 with 1% SDS. Total protein in all preparations was 
quantified with the micro BSA assay (Pierce) and all solutions were supplemented with 
protease and phosphate inhibitor cocktails (Sigma) as well as 1 mM sodium fluoride and 
sodium orthovanidate (Sigma). 
3.3  Sample preparation for LC-SRM/MS and LC-tandem MS (MS/MS):   
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Sample preparation for LC-SRM/MS and LC-tandem MS (MS/MS): Synaptic 
preparations were mixed with the [13C6] brain ISTD at a ratio of 2:1(μg/μg) and 
processed for MS analysis as described in Cheng et al. 2006.  Briefly, preparations were 
heated with LDS buffer at 95°C for 20 min, separated on a 1.5 mm 4-12% Bis-Tris Gel 
(Invitrogen), cut into three fractions for LC-SRM/MS and five for LC-MS/MS (Figure 3-
1C& D), chopped into ~ 2 mm cubes, washed in 50% acetonitrile (ACN) containing 25 
mM NH4HCO3, reduced with 10 mM DTT, alkylated with iodoacetamide (Sigma), and 
digested with trypsin (Promega) 1:5 by mass, overnight at 37°C.  Peptides were 
recovered from gel cubes into 50/50 H2O/ACN with 3% formic acid by vortex-mixing 
and sonication for 20 min each. Samples were then desalted with Oasis® HLB cartridges 
(Waters), filtered with 0.22 µm Ultra free-MC filter cartridges (Millipore), then dried 
almost to completion and suspended in 45μl H2O with .1% formic acid.   
3.4  MS methods:  
For LC-SRM/MS analyses, all peptide preparations were run on a TSQ Vantage 
triple stage quadrupole mass spectrometer (ThermoFisher Scientific) with an Eksigent 
2Dnano LC (Eksigent) and a CaptiveSpray source (Michrom).  5 μl (~2.5μg protein) 
sample was loaded on to a Magic C18 column (Michrom) at 1 μl/min for 12 min, and 
eluted at 750nl/min over a 25 min gradient from 3-35% mobile phase B (ACN containing 
.1% formic acid).   SRM transitions were timed using 1 – 1.5 min retention windows, 
depending on the number of SRMs to be assayed.  Transitions were monitored, allowing 
for a cycle time of 1 sec, resulting in a dynamic dwell time, never falling below 10 msec.  
The MS instrument parameters were as follows: capillary temperature 275 οC, spray 
voltage 1100 V, and a collision gas of 1.4 mTorr (argon).  The resolving power of the 
instrument was set to 0.7 Da (FWHM) for Q1 and Q3.  Data were acquired using a chrom 
filter peak width of 4.0 sec. 
 LC-MS/MS analyses were conducted by Dr. Gene Ciccimaro on a Q Exactive 
(ThermoFisher Scientific) quadrupole orbi-trap hybrid instrument with an Easy nLC-II 
(ThermoFisher Scientific) nano-pump/autosampler.  3μl peptide sample (~ 1 ug) was 
loaded and resolved on a 20 cm x 75 µm proteopepII C18 packed tip column over a 90 
min gradient at a flow rate of 350 nL/min, 0-35% mobile phase B (ACN, .1 formic acid).  
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A data-dependent top 10 method was used to acquire a 70,000 resolution full scan to 
trigger 10 17,500 resolution HCD scans.  Ions were isolated for MS/MS analysis with a 
2.0 Da window on the quadrupole.  Average cycle times were 1 sec.  Each sample was 
analyzed in triplicate.    
LC-MS/MS data analysis:  Raw files from triplicate injections were searched together 
within Proteome Discoverer 1.3 (ThermoFisher Scientific) using SEQUEST and the 
human refseq. database (release 47, 
ftp://ftp.ncbi.nih.gov/refseq/H_sapiens/mRNA_Prot/).  Search parameters allowed trypsin 
to cleave after Lysine and Arginine and have 2 missed cleavages.  Precursor ion mass 
tolerance was set to 15 ppm and fragment ion mass tolerance was 20 mmu.  The dynamic 
modification of methionine (oxidation = 15.995 Da) and lysine (13C6 = 6.020 Da), in 
addition to the static modification of cysteine (carbamidomethylation = 57.021 Da) was 
accepted on up to 4 residues per peptide.  Within the Proteome Discoverer Software, 
SILAC pairs were identified using the “2 plex” workflow node, and all peptides were 
rescored using the Percolator164algorithm node.  Finally, peptides were filtered at 1% 
FDR. 
SRM transition design and validation: Method development began with the selection 
of ~300 synaptic proteins of interest from published multidimensional MS/MS analyses 
of mouse and human brain tissue biochemical fractions109, 153 as well as the LC-MS/MS 
analysis described in this study.  RAW data from the two analysis of human tissue were 
searched in Proteome Discoverer™ 1.1(ThermoFisher Scientific) using SEQUEST.  
Proteome Discoverer™files were loaded into ProteinCenter™(ThermoFisher Scientific), 
and sorted by function and subcellular location using Gene Ontology (GO) terms.  
Targets for inclusion in the LC-SRM/MS assay were selected with a bias towards well-
annotated synapse proteins, such as glutamate receptors, kinases, phosphatases, vesicular 
fusion, amino acid metabolism, energy metabolism, protein trafficking, ion conductance, 
cytoskeleton, and scaffolding.  Peptides for proteins of interest were then filtered based 
on the following criteria: 1) presence of lysine to incorporate the “heavy” label, 2) non-
redundant to a selected protein or protein group (determined by BLAST search) and 3) 
100% homology across mouse and human sequences (determined by BLAST search).  
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Acceptable peptide sequences, along with MS2 spectra, were imported into Pinpoint™ 
(Thermo-Scientific).  Initially, five mass transitions were selected for each target peptide 
and its “heavy” counter-part.  Validation experiments were performed in 1:1 mixtures of 
human IM fraction and the [13C6] brain ISTD.  Pinpoint™ was used to visually and 
statistically validate SRM transitions.  
3.5  Western blot analysis  
To confirm biochemical enrichment, all preparations were assayed by Western 
blot for parasynaptic (P), postsynaptic (D) and vesicular (V) proteins prior to MS analysis 
(27). Briefly, 10μg of each fraction was separated on 7.5% SDS precast gels (Biorad), 
transferred to a PVDF membrane (Millipore), blocked with 5% milk, .05% TBST for 30 
min, and probed with the following antibodies: mouse monoclonal PSD-95, 1:1000 
(Upstate or NeuroMab, UC Davis, CA), Na/K ATPase channel subunit α 1:1000 (Santa 
Cruz) and Gα 1:500 (Cell Signaling).  The blots were developed using chemilluminescent 
reagents ECL or ECLPlus, or a combination of both (GE Healthcare).  
3.6  Modeling of Postmortem Interval in Mice   
Modeling of Postmortem Interval in Mice: 10 male 8-12 month old C57/B6 mice 
were sacrificed by CO2 and cervical dislocation, per protocol, and placed at 4°C. The 
brains were removed from the crania at 0, 4, 8, 12 and 16 h post sacrifice, separated from 
the cerebellum and olfactory bulbs, frozen on dry ice, stored at -80°C and subject to 
biochemical fractionation.  The D fractions were analyzed by LC-SRM/MS as described 
above. 
3.7 LC-SRM/MS data and statistical analysis  
Peak areas and area ratios were calculated within Pinpoint.  Raw files generated 
by LC-SRM/MS analysis were loaded into Pinpoint files containing target 
proteins/peptides/transitions.  All individual SRM transitions and integration areas were 
manually inspected.  Transitions where the signal-to-noise (S/N) ratio of the “labeled” 
species below 3 were excluded from analysis.  The ratios of the integrated areas for 
“light” endogenous peptides and “heavy” [13C6]brain ISTD peptides were calculated to 
obtain peptide measures using multiple transitions per peptide.  The average of these 
peptide ratios determined the relative amount of each protein.  Protein enrichment values 
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in the SF, V, P and D fractions were calculated by normalizing protein measures in each 
fraction to measures in the H fraction.  The coefficient of variations (CV), expressed as a 
percent, were calculated to assess precision of peptide quantification across injections, 
accuracy of protein quantification from multiple peptides, and reproducibility of 
fractionation from different animals or subjects. 
Unsupervised hierarchical clustering was used to construct self-organized heat 
maps of protein and fraction by enrichment values with Cluster 3.0 and Treeview165, 166.  
Enrichment values were log2 transformed, median centered by enrichment and fraction, 
then normalized by protein and fraction.  Un-centered Pearson correlation was used as the 
similarity metric and the clustering method was centroid linkage. Pearson correlation 
coefficients were calculated in Cluster 3.0. ANOVA, and Student’s t-test were used to 
calculate significance for the effects of species and fraction on enrichment CVs, species 
and protein group on enrichment values, and PMI and protein group on protein measure.   
3.8  Dilution curve preparation 
 To confirm that “light”/”heavy” peptide SRM measures were within linear range, 
a dilution curve was prepared by varying the ratio of a human  total homogenate (H) 
fraction /  [13C6]brain ISTD from 0.05 to 19. Five mixtures were prepared, (μg H/ μg  
[13C6]brain ISTD): 1/19, 3/17. 10/10, 17/3 and 19/1. These preparations were analyzed by 
LC-SRM/MS in duplicate and the prepared L/H ratio plotted against the observed L/H 
ratio for each light-heavy peptide pair.  
3.9  Comparison of human and mouse protein sequences 
Dr. Steve Seeholzer graciously performed this analysis. Human and mouse 
protein sequence databases were assembled from the orthologous protein accessions 
listed in the HomoloGene database (http://www.ncbi.nlm.nih.gov/homologene, release 
65).  The Entrez efetch utility was used to retrieve the mouse and human fasta format 
sequences from the Entrez protein database.  Proteins were digested in silico with trypsin 
while retaining peptides ending with lysine and 6 ≤ length ≤ 25.  Human peptides were 
additionally filtered to retain only proteotypic peptides.  For each human protein, the 
number of peptides having an identical amino acid sequence to any mouse peptide was 
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tabulated.  A separate analysis was limited to the 1400 proteins identified in a proteomic 
study of mouse (Bl6) synaptosomes (Seeholzer and Kalb, unpublished).  
4. Results 
4.1 LC-MS/MS analysis of postmortem human brain intermediate 
membrane fraction spiked with [13C6] brain ISTD:   
The combined analysis of all five gel bands resulted in the identification of 2,556 
protein groups by 2 or more unique peptide sequences.  In total, 230,841 peptide spectral 
matches were attained, allowing for 27,650 unique peptide sequence identifications.  
2,802 labeled lysine containing peptides were identified, while 2,211 were 
bioinformatically unique to a single protein group and 1,798 were observed as a 
“heavy/light” pair.  The median heavy/light ratio was 0.27.  Supplemental Figure 3-1A 
shows the ratio distribution of all observed unique peptide pairs.  These unique labeled 
peptide pairs corresponded to 619 proteins, 325 of which were represented by 2 or more 
unique pairs.  Supplemental Figure 3-1B shows the protein distribution by the number of 
unique peptide pairs. Dr. Gene Ciccimano performed this analysis.  
4.2 Fidelity of Peptide SRMs 
To ensure that the desired peptide was assayed, rigorous selection criteria were 
employed for the inclusion of peptide LC-SRM/MS transitions.  After a peptide met the 
three initial criteria described above: non-redundancy, presence of lysine and 100% 
sequence homology between mouse and human tissues, multiple validation experiments 
were conducted to confirm peptide SRM accuracy.  Candidate “light”/“heavy” peptide 
SRMs were evaluated for A) retention time, B) similar y-ion ratios (within 25%), C) 
presence in the correct gel fraction, and D) a signal to noise greater than 3.  Peptide SRM 
pairs for which more than one identical peak was observed were omitted. Out of the 
approximately 300 initial proteins selected, 2-4 SRMs for 1-4 peptides from 189 proteins 
met these criteria (Sup. Table 3-1, Appendix 2).  Of these 189, 110 were measured by one 
peptide, 53 by two, and 25 by three or more. 
4.3 Precision of Protein Quantification 
To assess LC-SRM/MS technical precision, four 30 μg aliquots of a human 
intermediate membrane fraction were individually mixed with 15 μg [13C6] brain ISTD, 
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prepared for LC-SRM/MS analysis and injected in triplicate over several days.  A subset 
of 118 proteins was monitored in this experiment.  First, analytical precision of peptide 
quantification over repeated injections was assessed.  The median CV for peptide 
measures across three repeated injections was 4.3% and CV correlated with the signal 
intensity of the light peptide SRM (R2 = .7) (Supplemental Figure 3-2).  Variability from 
sample preparation was also assessed. The median CV% across 4 repeated preparations 
was 3.8%, with the vast majority under 10% (Figures 3-2A&B).  Finally, we assessed 
precision of protein quantification by calculating variability between the peptides that 
were quantified for the same protein. The median CV for proteins quantified with two or 
more peptides was 12%, with the majority of CVs being under 20% (Figure 3-2D).  This 
indicates that LC-SRM/MS with a [13C6]brain ISTD has excellent precision and highly 
reproducible sample preparation. 
4.4 Quantitative Analysis of Subcellular Fractions 
We analyzed the relative protein composition of five neuronal biochemical 
fractions: Homogenate (H), Synaptosomal (SF), Vesicular (V), Pre-synaptic density (P) 
and Post-Synaptic density (D), prepared from three human postmortem prefrontal cortex 
sections and three mouse brains (Figure 3-1). Enrichment was confirmed by Western blot 
for protein markers of fractions D, V and P (Figure 3-3).  The enrichment of all fractions 
except for P from mouse 3 was confirmed. This preparation was analyzed with the other 
samples and included in hierarchical clustering, but was dropped from average 
enrichment and enrichment variability calculations.  The fractions were mixed, 2:1 by  
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Figure 3-2. Precision of peptide quantification. To assess variability in sample preparation, 
four 30 μg aliquots of a human IM fraction were individually mixed with 15 μg [13C6]brain 
ISTD, and analyzed by LC-SRM/MS with triplicate injections. The coefficient of variance, 
expressed as a percentage (CV%), was calculated for each peptide measured in the four 
fractions.  A, depicts the distribution of the peptide CV%s, showing the vast majority under 
10%. B, shows light/heavy area ratios for the TYATAEPFIDAK peptide, which is unique to 
Synapsin I. Error bars are standard deviations (SD) of the triplicate injections.  C, 
chromatographic peaks from LC-SRM/MS analysis of TYATAEPFIDAK. CV% of peptide 
measures for the same proteins were calculated to assess accuracy of protein measures derived 
from multiple peptide SRMs. D, shows the distribution of these CV%s.  E, shows the 
consistency of peptide measures for the same protein across 6 fractions prepared from human 
subject 1. 
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mass, with [13C6]brain ISTD, separated into three fractions by SDS-PAGE (Figure 3-1C) 
and analyzed by LC-SRM/MS with duplicate injections (Sup. Table 3-1, Appendix 2).  
To ensure a continued high level of precision in peptide and protein measurement, 
peptide SRMs in this data set were re-evaluated for variability, intensity and signal-to-
noise ratio using the criteria described above.  Additionally, as post-translational 
modifications can confound protein measurements derived from peptide SRMs, peptide 
trends across different fractions from the same individual were manually inspected for 
consistency, as in Figure 3-2E.  Proteins lacking consistent peptide measures were 
removed.  It is important to note that even minute differences in peptide measurement for 
the same protein were consistent across all fractions.  For example the 
AVFQANQENLPILK peptide, from Na/K ATPase subunit alpha-1, was slightly elevated 
in all fractions compared to the other two peptides (Figure 3-2E).  The 150 proteins that 
met these criteria in both human and mouse preparations were used as the basis for 
comparing fractionation between the two species (Sup. Table 3-2, Appendix 2).   
4.5 Protein and peptide quantification accuracy 
Accuracy of protein measures was assessed by comparison with Western blot for 
three synaptic proteins: guanine nucleotide binding protein subunit α, sodium/potassium 
ATPase channel subunit α 1 and PSD-95.  We observed consistent agreement in relative 
protein measures between the two methods (Figure 3-3). 
The light/heavy peptide ratios were found to be linear over the range of the 
dilution curve for most peptides, with some deviating from linearity at the first and/or last 
point. The average R2 for 195 peptides assayed was .96. Figure 3-4 shows representative 
dilution curves for CaMKIIα, CDK5, NR1 and PSD95.  
4.6 Protein enrichment 
Protein enrichment values were calculated by normalizing protein measures in the 
SF, V, P and D fractions to protein measures in the H fraction.  Averages and CVs of 
protein enrichment values and protein measures in H were calculated for each species.  
Median CVs for enrichment values were under 30% for all preparations from both 
species (Figure 3-4A).  In four of the five preparations (H, SF, P and D) the average CV 
was significantly lower in mice, but a two-way ANOVA did not reveal a significant 
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interaction between species and 
fraction p = 0.2.  A substantial 
number of proteins had CVs 
above 30% (Supplemental 
Figure 3-3). At first, we 
suspected that proteins with 
high CVs in a fraction would 
have low average enrichment 
values, while more abundant 
“bona fide” proteins would 
have more consistent values.  
Regression analysis, however, 
found no correlation between 
average enrichment value and 
CV in any of the fractions (data 
not shown), necessitating the 
sorting of proteins by both 
enrichment value and 
variability.  
To gain this more 
comprehensive view of the 
data, unsupervised hierarchical 
clustering was used to group 
proteins and fraction by protein 
enrichment value (Appendix 3, 
Sup. Figures 3-6, 3-7 & 3-8).  
In both species we observed 
segregation of preparations 
into discreet groups by fraction 
identity (Figure 3-5B & C).  
Figure 3-3. Confirmation of protein enrichment in 
biochemical fractionation and accuracy of protein 
quantification. Prior to LC-SRM/MS analysis, Western 
blot was used to confirm success of biochemical 
fractionation.  Levels of Na/K ATPase channel subunit 1 
α, guanine nucleotide binding protein subunit α, and 
PSD-95 were used to confirm enrichment of vesicular 
(V), parasynaptic (P) and postsynaptic density (D) 
fractions, respectively. LC-SRM/MS quantification of 
these proteins was then compared to Western blot. A, B 
and C, show representative blots and LC-SRM/MS area 
ratios from human subject 2.  Error bars are standard 
deviations of duplicate injections. 
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Clustering analysis of human and mouse preparations together revealed that biochemical 
fractions within species had the tightest grouping, followed by fraction identity, 
regardless of species (Figure 3-5D).  Many protein groups clustered by high enrichment 
values were both similar across species and in agreement with previously published 
analyses of these preparations.  Kinases, scaffolding proteins and glutamate receptors 
were enriched in postsynaptic density (D) fractions (Figure 3-6A, Supplemental Figure 
8A), SNARE complex proteins and vesicular amino acid transporters were enriched in 
vesicular (V) fractions (Sup. Figure. 3-8B), and guanine nucleotide binding protein 
subunits and voltage-dependent ion channels were enriched in parasynaptic (P) fractions 
(Sup. Figure 3-8C).  Synaptosomal (SF) fractions were rich in cytosolic enzymes (Sup. 
Figure 3-8D).  Clustering analysis of human and mouse fractions together also 
highlighted two striking differences 
between mouse and human preparations. 
First, it identified a subset of 
“contaminant” proteins that were enriched 
in human D fractions, but not in mouse 
fractions (Sup. Figure 3-8E).  Second, all 
septin proteins measured were enriched in 
mouse D and P fractions, but not in human 
fractions (Sup. Figure 3-8F) 
The enrichment values were 
heavily processed prior to hierarchical 
clustering. To more closely investigate the 
similarities and differences between 
human and mouse preparations, we 
compared the average enrichment values 
for the protein groups identified by the 
clustering analysis in V and D.  In the V 
fraction, enrichment values for vesicular 
proteins were more similar to each other in mice, as compared to humans (Figure 3-6B & 
Figure 3-4. Representative dilution curves.  
A human total homogenate fraction (H)  was 
mixed with the [13C6]brain ISTD in the 
following ratios (μg): 1/19, 3/17. 10/10, 17/3 
and 19/1. These preparations were analyzed 
by LC-SRM/MS in duplicate and the 
prepared L/H ratio plotted against the 
observed average L/H peptide ratio (peptide 
measure) for each protein. This figure 
show’s representative curves for  CaMKIIα, 
CDK5, NR1 and PSD95. The 19/1 point is 
not shown to highlight the midrange of the 
curve, but does not deviate from the slope 
reported here.  
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D).  In D, enrichment values for kinases, scaffolding proteins and glutamate receptors 
were roughly twice as high in mouse (Figure 3-6C & E).  A two-way ANOVA confirmed 
a significant interaction between species and the protein group for average enrichment 
value (p < 0.0001).  Enrichment values for the “contaminant” proteins were, on average, 
12-fold higher in the human D compared to mouse (p = 0.022), the most extreme of 
which was creatine kinase brain isoform with a 72-fold higher enrichment value (Sup. 
Figure 3-4A).  The septins had, on average, 3-fold higher enrichment values in the mouse 
D compared to human D (p = 0.017) (Sup. Figure 3-5). Interestingly, we observed some 
reciprocal enrichment between the D and SF fractions for both of these protein families 
(Sup. Figures 3-4 and 3-5).  
To test if postmortem interval (PMI) contributed to these differences, we analyzed 
D fractions prepared from mouse tissues with PMIs ranging from 0 to 16 h.  Measures of 
“contaminant” proteins in D increased with PMI, while measures for glutamate receptors 
and scaffolding proteins decreased (Sup. Figure 3-4C & D). A two-way ANOVA 
confirmed a significant interaction between the two protein groups, PSD proteins vs. 
contaminants, over PMI (p = .007).  The protein measures for the septins in fraction D, 
however, increased steadily to a PMI of 12 h, before decreasing after 16 h (Sup. Figure 3-
5C). 
5. Discussion 
Deregulated synaptic activity is implicated in a host of neurological and psychiatric 
diseases, but strategies to address synaptic protein function in human postmortem brain 
tissues are limited.  Many neuropsychiatric diseases, such as autism, depression and SCZ, 
are believed to arise from complex interactions between many synaptic signaling 
cascades in specific subcellular microdomains74, 75, 88, 156-158, the remnants of which are 
present in the postmortem brain tissues of patients.  Therefore, the ability to assess 
protein expression and trafficking events in postmortem brain tissue, with high precision 
and accuracy, is essential.  Various MS-based proteomics strategies have been applied in 
rodent and non-human primate tissue, with limited application in postmortem human 
tissue109, 111, 116, 155.  Here we report, for the first time, the targeted and precise relative 
quantification of over 150 synaptic proteins in 5 distinct sub-cellular preparations from 
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human postmortem brain tissues.  This study demonstrates that the core protein 
components of synaptic microdomains are consistently enriched in biochemical fractions 
prepared from human tissue.  Additionally, we identified proteins whose partitioning 
through fractionation is affected by PMI and other postmortem confounds.  This 
validated fractionation – stable isotope dilution LC-SRM/MS methodology will further 
the investigation of synaptic function in a variety of neuropsychiatric diseases.  
5.1 LC-SRM/MS 
LC-SRM/MS with a 13C6-brain ISTD allowed the simultaneous quantification of over 
150 proteins with precision and reproducibility.  We observed low variability in peptide 
measures over repeated injections (Sup. Figure 3-2) and preparations (Figure 3-2), as well 
as a high level of accuracy in protein quantification as assessed by multiple peptide 
SRMs (Figure 3-2), Western blot (Figure 3-3) and dilution curve (Figure 3-4).  Although 
the analytic precision correlated with intensity of the analyte signal (R2 = 0.7), the 
median CV for peptide quantification was 4.3% with the majority of peptides < 10% 
across three orders of magnitude of signal intensity (Figure 3-2 and Sup. Figure 3-2).  
This compares favorably with other multiplexed protein quantification strategies. For 
example, antibody based protein arrays, when applied to similar protein preparations 
from human postmortem brain tissue, have an average CV of 14% (personal 
communication, Dr. Steve Arnold, unpublished data).  The [13C6]-brain ISTD was critical 
for this high precision over such a large dynamic range.  This standard is prepared from 
[13C6]lysine SILAM mouse brain tissue, and thus contains labeled peptides at ratios close 
to those found in human brain tissues.  To better approximate the protein levels we 
expected to observe in synaptic fractions, as well as to obtain a “simpler” standard 
proteome, we prepared a crude membrane fraction from the labeled mouse brain tissue to 
serve as the [13C6]-brain ISTD.  This mouse [13C6]-brain ISTD was mixed with the 
intermediate membrane fraction from human brain 1:2 (μg/µg), and a bottom up analysis 
was conducted on the mixed proteome following a simple gel fractionation, in order to 
verify protein levels between the proteomes, as well as to identify additional candidate 
peptide pairs for targeted SRM analysis.  The results showed peptide pairs with  
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Figure 3-5. Overview of protein enrichment. Protein enrichment values were calculated for 
each protein in the SF, V, P and D fractions by normalizing measures in each fraction to 
protein measures in H.  The averages of these values for each fraction were then taken for the 
three human and three mouse samples and CV%s calculated. A, reports the median CV% of 
protein enrichment values for each fraction.  To sort out protein groups and fraction by 
enrichment value, unsupervised hierarchical clustering, with Pearson's Correlation as the 
similarity metric, was utilized.  B, shows clustering analysis of the mouse fractions as a heat 
map, C, the human and D, the mouse and human together. E, is the legend for B, C and D, 
numbers are arbitrary normalized enrichment values. For full heat maps with protein rows 
labeled, see Appendix 3.  
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Figure 3-6. Comparison of human and mouse vesicular and postsynaptic density 
fractions. A, a zoomed-in image from Figure 4D, depicts enrichment of postsynaptic density 
proteins in D fractions prepared from human and mouse tissues. The Pearson's Correlation 
Coefficient for this grouping was .72.  To more closely contrast human and mouse fractions, 
we compared enrichment values for a subset of the proteins grouped in the clustering analysis. 
B, shows enrichment of vesicular proteins in the human (V) fraction and D, those proteins in 
the mouse V fraction, while C and E show enrichment of kinases, scaffolding proteins and 
glutamate receptors in the human and mouse D fractions. Error bars are standard deviations of 
three individuals/animals.  Note that in C and E, protein enrichment is higher in the fractions 
prepared from mouse tissue.  
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methodology will further the investigation of synaptic function in a variety of 
neuropsychiatric diseases. 
5.1 LC-SRM/MS 
LC-SRM/MS with a 13C6-brain ISTD allowed the simultaneous quantification of 
over 150 proteins with precision and reproducibility.  We observed low variability in 
peptide measures over repeated injections (Sup. Figure 3-2) and preparations (Figure 3-
2), as well as a high level of accuracy in protein quantification as assessed by multiple 
peptide SRMs (Figure 3-2), Western blot (Figure 3-3) and dilution curve (Figure 3-4).  
Although the analytic precision correlated with intensity of the analyte signal (R2 = 0.7), 
the median CV for peptide quantification was 4.3% with the majority of peptides < 10% 
across three orders of magnitude of signal intensity (Figure 3-2 and Sup. Figure 3-2).  
This compares favorably with other multiplexed protein quantification strategies. For 
example, antibody based protein arrays, when applied to similar protein preparations 
from human postmortem brain tissue, have an average CV of 14% (personal 
communication, Dr. Steve Arnold, unpublished data).  The [13C6]-brain ISTD was critical 
for this high precision over such a large dynamic range.  This standard is prepared from 
[13C6]lysine SILAM mouse brain tissue, and thus contains labeled peptides at ratios close 
to those found in human brain tissues.  To better approximate the protein levels we 
expected to observe in synaptic fractions, as well as to obtain a “simpler” standard 
proteome, we prepared a crude membrane fraction from the labeled mouse brain tissue to 
serve as the [13C6]-brain ISTD.  This mouse [13C6]-brain ISTD was mixed with the 
intermediate membrane fraction from human brain 1:2 (μg/µg), and a bottom up analysis 
was conducted on the mixed proteome following a simple gel fractionation, in order to 
verify protein levels between the proteomes, as well as to identify additional candidate 
peptide pairs for targeted SRM analysis.  The results showed peptide pairs with 
heavy/light ratios ranging from .01 to 100 with a median of 0.27, below the prepared ratio 
of 0.5 (Supplemental Figure 3-1A). These discrepancies are unsurprising considering that 
different protocols were used to fractionate the tissues; the priority for human tissue 
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enrichment was purity, while the labeled mouse tissue was prepared with yield as the 
primary objective. 
LC-SRM/MS analysis using a [13C6] brain ISTD has several advantages over 
multi-dimensional separation tandem MS strategies for protein quantification by several 
of the criteria laid out in Chapter 1.  First, time requirements for both experiment and data 
analysis are greatly reduced.  Sample preparation time is reduced, as compared to strong 
cation exchange, since gel fractionation yield a minimal number of fractions and allows 
for multiplexed sample preparations within a single gel.  Indeed, it is likely that for 
relatively “simple” proteomes, the first dimension of separation could be omitted. 
Gradients for SRM/MS are much shorter than tandem MS approaches in which full 
MS/MS data for peptide identification must be collected.  Software, such as Pinpoint and 
Skyline, has streamlined peptide SRM design, validation and analysis. We validated 189 
proteins for LC-SRM/MS quantification with the [13C6] brain ISTD. This number is 
dwarfed by multi-dimensional separation tandem MS strategies that utilize labeled ISTDs 
or isobaric labeling.  However, our bioinformatics analysis indicates that this strategy 
could theoretically be applied to 1152/1189 synaptic proteins (Figure 3-7), 1024 of which 
have peptides (proteotypic, ending in lysine, 6 ≤ length ≤ 25) that have been identified in 
the NIST peptide database. As these libraries grow from incorporation of our own and 
others’ discovery data, so will the number of proteins that can be assayed.  Additionally, 
this methodology will allow researchers to target specific protein families and/or 
pathways.  Posttranslational modifications are often present in low amounts and can only 
be assayed by the observation of a specific peptide, while proteins can be quantified by 
numerous peptides.  Thus, multi-dimensional separation tandem MS strategies can be ill 
suited for the reproducible quantification of protein posttranslational modification 
compared to the targeted peptide SRM strategies. 
5.2 Comparison of preparations from mouse and human tissues 
Chapter 2 reported that postsynaptic densities could be fractionated from the 
majority of human postmortem brain tissues153. Here, I utilized the accuracy and 
precision of LC-SRM/MS with a [13C6]-brain ISTD to further examine the reproducibility 
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of subcellular fractionation in human postmortem brain tissue.  I compared the relative 
enrichment of over 150 proteins in 4 fractions (SF, V, P & D) prepared from the 
prefrontal cortexes of three human subjects and the brain tissues of three mice (Figure 3-
1). 
Mouse brains, flash frozen on dry ice immediately after dissection, are mostly free 
of the postmortem confounds, as well as individual variability, inherent to human brains. 
In these tissues the median variability of protein enrichment was under 30% for all 
fractions (Supplemental Figure 3-3).  Unsupervised hierarchical clustering of proteins 
and fractions by enrichment values revealed tight grouping of fraction types (Figure 3-
5B).  The clustering analysis also returned enriched protein groups in line with current 
views of synaptic architecture (see Results).  Despite the fact that the P fraction from 
mouse #3 was identified as an outlier, it still clustered with the other two P fractions 
(Sup. Figure 3-6A), demonstrating the power gained from comparing multiple protein 
measures. 
Human and mouse preparations were compared by enrichment value variability, 
hierarchical clustering and relative enrichment levels.  Variance in protein expression and 
enrichment values tended to be smaller in preparations from mouse tissue (Figure 3-5A, 
Sup. Figure 3-3). Considering the individual variability in the humans from which tissue 
was derived, most notably age (70, 72 & 98), sex (2F, 1M) and PMI (4, 10 and 15 hours), 
protein enrichment in human fractions should be considered rather consistent. Hierarchal 
clustering also revealed a striking similarity in enrichment patterns between the same 
fractions prepared from different species, while highlighting some key differences 
(Figure 3-5D).  The enrichments that drove this clustering were composed of well-
documented synaptic molecules (Sup. Figure 3-8).  Subcellular fractions prepared from 
human tissue are consistently enriched for key synaptic proteins in a manner similar to 
mouse tissue, suggesting that the core protein complexes that make up these 
microdomains are relatively intact in human postmortem brain despite biochemical 
procedures for fractionation. Indeed, our group has previously shown that protein-protein 
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interactions at PSD95, a central protein in postsynaptic protein complexes, are preserved 
in human brain tissue and survive biochemical fractionation153. 
I observed distinct differences between flash frozen mouse and postmortem 
human brain tissues. First, although PSD proteins were enriched in D fractions from both 
species, the enrichment values were 2x higher in fractions prepared from mice (Figure 3-
6).  I also identified a subset of “contaminant” proteins enriched in D fractions prepared 
from humans, but not from mice (Sup. Figures 3-4 and 3-8).  Interestingly, some of these 
proteins were enriched in SF fractions from mice, but none were enriched in human SF 
(Sup. Figures 3-4B and 3-8).   These proteins are diverse in both function and cellular 
localization, suggesting tissue degradation over PMI could cause co-enrichment in the D 
fraction, diluting the relative amount of postsynaptic density proteins.  Experiments with 
D fractions prepared from mouse brain tissues with simulated PMIs support this 
assertion.  I observed increased amounts of these “contaminant” proteins with decreased 
amounts of postsynaptic density proteins as PMI increased (Supplemental Figure 3-4C & 
D).  Finally, septin proteins were enriched in the D and P fractions from mice, but not 
from humans (Supplemental Figures 3-5 and 3-8).  Septins are conserved eukaryotic 
proteins that form cytoskeleton components that provide membrane rigidity and create 
barriers between subcellular domains in many cell types, including neurons167.  
Additionally, more specialized roles for individual septin family members have been 
identified on both sides of the synapse. For example, Septin 5 has been shown to inhibit 
vesicle exocytosis by interacting directly with the SNARE complex168, 169, while Septin 
11 plays a functional role in dendritic arborization of GABAergic synapses170. PMI could 
not explain the differences in enrichment as septin proteins increased with PMI, in 
contrast to the observations in human tissue (Supplemental Figure 3-5C).  While 
individual septins have known roles at the synapse, the septin cytoskeletons have not 
been observed to associate tightly with postsynaptic protein complexes114, 133, 156. In 
addition to PMI, another difference between mouse and human tissue is the ratio of white 
to grey matter. Human cortex samples are cut to maximize the amount of grey matter in 
the tissue sample, while it is not possible to separate the two in mouse brain. I suspect 
60 
 
this composition of human tissue yields a more pure D fraction in terms of septin 
contamination.  Further experiments, ideally in grey matter dissected from fresh-frozen 
non-human primate tissue, are required to confirm this hypothesis. 
Neuropsychiatric illnesses are associated with alterations in synaptic biology, 
which involve a multitude of proteins and signaling mechanisms in a microdomain-
specific manner.  The ability to assay the proteomes of synaptic microdomains, in which 
disease factors may converge, is essential to advancing our understanding of these 
illnesses.  Here, I have validated a fractionation – stable isotope dilution LC-MS 
methodology for the precise and targeted quantitation of over 150 synaptic proteins in 
subcellular fractions prepared from human postmortem brain tissue.  Additionally, we 
have demonstrated that this method has the potential to be expanded to >1000 synaptic 
proteins.  Thus, this study represents the essential first step in bringing targeted proteomic 
strategies to bear on the study of neuropsychiatric disease in human brain tissue. 
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Figure 3-7. Comparison of human and mouse protein sequences. Protein sequences were 
retrieved for human and mouse homologenes from the total proteome and a representative 
synaptic proteome. Lysine-containing peptides, between 6 and 25 amino acids in length, were 
compared between the two species.  This analysis shows that the [13C6]brain ISTD can 
theoretically be used to quantify 80% of the human synaptic proteins identified by more than 
two peptides. Additionally, the vast majority of these synaptic proteins have peptides in the 
NIST Libraries of Peptide Tandem Mass Spectra. 
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CHAPTER FOUR  
ALTERED PARTITIONING OF POSTSYNAPTIC 
DENSITY COMPLEXES IN SCHIZOPHRENIA  
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1. Abstract  
Several lines of evidence point to the PSD as point of convergence for SCZ 
genetic risk factors. PSD signaling is crucial for regulating NMDA rector function, which 
is perturbed in SCZ and believed to underlie aberrant plasticity.  Additionally, decreased 
dendritic spine density has been consistently observed in layers 2 and 3 of the DLPFC in 
SCZ patients. Decreased PSD protein expression seems a likely correlate for decreased 
spine density, while alter PSD complex protein composition could contribute to NMDA 
receptor hypofunction in the DLPFC of SCZ.  Interesting, investigations by traditional 
methods, qPCR, Western blot and in-situ hybridization, have not consistently observed 
decreased PSD protein expression and few studies have investigated the protein 
composition of synaptic microdomains in postmortem tissues.  
To investigate PSD protein expression and partitioning, the biochemical 
fractionation - [13C6]-brain ISTD - LC-SRM/MS method, developed and validated in 
Chapter 3, was utilized. 185 proteins were quantified in whole tissue homogenates 
prepared from 15 pairs of SCZ subjects and matched controls. 107 proteins were 
quantified in PSD enrichments from 9 pairs. Protein expression was largely unaltered 
between SCZ and control tissues, while enrichment of PSD proteins was elevated in 
preparations from SCZ subjects.  Despite this enrichment, the relative amounts of 
postsynaptic proteins, normalized to PSD95, was unaltered between the two groups.  
These changes could not be attributed to neuroleptics effects, assayed in the PFC tissue of 
rhesus monkeys and did not correlate with PMI or subject age. These data suggest that 
partitioning, not expression, of PSD complex proteins is the major molecular correlate of 
decreased spine density in the LPFC of SCZ.  
2. Introduction  
 Several lines of evidence point to the PSD as a microdomain that will be critical 
for the pathophysiology of SCZ: 1) NR hypofunction is widely believed to be a key 
component for the pathophysiology of SCZ, hypothesized to be present both throughout 
development and in the tissue of elderly patients6, 72, 78, 88. Given that NR complexes are 
highly concentrated in the PSD129, 146 and NR activity is critically modulated by PSD 
protein composition44, 59, it is highly likely that such functional dysregulation of NRs is 
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associated with altered PSD protein compositions and/or interactions.  2) Several SCZ 
risk genes, e.g. ErbB4, NRG1, RGS4 and DISC1 directly impact NR signaling at the 
PSD72, 74, 77, 88, implicating the PSD as a point of convergence for genetic factors.  3) NR 
and PSD complexes are localized to the spines of excitatory synapses. Decreased spine 
density has been observed in layers 2 and 3 of the DLPFC without neuronal loss35, 36, 43. 
Decreased spine density is likely the result of perturbed neuroplasticity caused by NR 
hypofunction94, 171.   Thus, dysregulated PSD protein expression and partitioning could be 
both cause and consequence of SCZ disease processes. NR hypofunction and the genetics 
of disease risk implicate altered PSD protein dynamics, as a cause of dysfunctional 
neuroplasticity, while decreased spine density, believed to be the consequence of 
dysfunctional neuroplasticity, suggests that PSD protein expression should be decreased 
in the DLPFC.   
 A myriad of strategies have been employed to investigate postsynaptic protein 
and transcript levels in the PFC tissues of SCZ subjects in an effort to observe the 
predicted molecular dysregulations.  However, the results of these studies have been 
contradictory (See Table 1-1 for a review of recent findings).  While many groups 
observe no difference in protein expression between control and disease tissues, other 
groups report small differences in one or two mRNA transcripts97-105, but often with low 
statistical significance, and without controlling for multiple hypothesis testing. Presently, 
there are no consistently observed changes in mRNA or protein expression of PSD 
proteins in SCZ. 
 This lack of consistent observations is perhaps not surprising considering the 
complexity of predicted synaptic protein expression and partitioning changes, as well as 
the technical hurdles protein and mRNA strategies must overcome to measure them.  
Histological studies have the advantage of being able to visualize the object of study (the 
spine) allowing for unit quantification and a spatial resolution not achievable in other 
molecular assays such as Western blot, real-time PCR and microarray.  As for mRNA 
quantification, great progress has been made in resolving cortical layers and neuronal 
sub-populations106-108. However, while the results of these studies are extremely 
informative, they may not be reflective of protein levels in whole cells or spines of 
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human postmortem tissue. Likewise immunohistochemistry has special resolution for 
protein amounts, but is limited in the number of proteins that can be assayed.  
Inconsistencies between mRNA and protein findings in the DLPFC of SCZ 
patients could be explained by the following: 1) Current approaches lack the sensitivity, 
spatial resolution and, in the case of protein assays, multiplexed capability to observe the 
altered protein expression expected to parallel decreased spine density and NR function. 
2) The predicted molecular correlates of decreased spine density and NR activity are not 
manifested in mRNA and/or protein expression levels, but in altered partitioning, 
interactions and posttranslational modifications. 3) Both 1 and 2. That is, protein 
expression is unaltered and current approaches lack the precision and resolution to 
confirm the null hypothesis with high confidence.  
Clearly, approaches with enhanced 
sensitivity, spatial resolution and multiplexed 
capability, among other methodological 
improvements are required to overcome these 
technical issues and elucidate the molecular 
correlates of decreased dendritic spine and NR 
hypofunction. This study represents an attempt to 
address some of these technical issues and 
perform a more thorough search for molecular 
perturbations in the PFC of SCZ. Here, 
biochemical fractionation and [13C6]-brain ISTD-LC-SRM/MS were utilized for the 
multiplexed quantification of over 200 synaptic proteins in whole tissue homogenates and 
over 100 proteins in biochemical PSD enrichments. This approach allowed for the 
precise, accurate and multiplexed quantification of synaptic protein expression and 
partitioning to the PSD. While this method has spatial resolution for a synaptic 
microdomain, the PSD, it cannot resolve between cortical layers or neuronal subtypes. 
Thus the experiments described below represent a first step in deciphering the molecular 
complexity of the synapse in SCZ.  
3. Materials and Methods 
Figure 4-1. Subject age and 
postmortem interval. A, shows 
subject  postmortem interval (PMI) 
in hours (h). B, shows subject age in 
years (y).  
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3.1 Human lateral frontal cortex tissue 
Psychiatric subjects met Diagnostic and Statistical Manual of Mental Disorders 
Fourth Edition (DSM-IV) diagnostic criteria for SCZ. Diagnosis was determined by 
consensus of at least two board-certified research psychiatrists after comprehensive 
review of medical records, direct clinical assessments and interviews with caregivers. 
Autopsy consent was obtained from the next of kin or a legal guardian in all cases, based 
on a protocol approved by the Institutional Review Board at the University of 
Pennsylvania. Control and psychiatric subjects were matched for sex, age, smoking 
history and postmortem interval (Sup. Table 4-1 and Figure 4-1). 
3.2 Rhesus monkey PFC tissue 
Dr. Scott Hemby (Wake Forrest University) generously supplied DLPFC tissue 
from rhesus monkeys treated with treated with different neuroleptics for six months: 
clozapine (5.2 mg/kg daily dose), low does haloperidol (0.14 mg/kg daily dose), high 
dose haloperidol (2.0 mg/kg twice daily) and vehicle. Each group consisted of five males 
and five females with the exception of the high haloperidol group, which had four of 
each. These animals are extensively described elsewhere 172. Only tissue from the male 
animals was utilized for the experiments described here, while the females will be 
analyzed at a later date.  
3.3 Biochemical fractionation 
Whole tissue homogenates and PSD enrichments from the lateral PFC (LPFC) of 
30 subjects were prepared in three batches (Sup. Table 4-1). Batch 1 was prepared using 
a variation of the protocol described in Chapter 3, section 3.2, that omitted the 2500 RPM 
spin after the homogenization step.  Batch 2 was prepared using the protocol described in 
Chapter 3, section 3.2. Due tissue amount limitations, the remaining human tissue and all 
rhesus monkey tissues were processed using an abridged protocol: 
50 mg grey matter was homogenized in .5 ml solution A (0.32 M sucrose, 1mM 
MgCl2 and 0.1mM CaCl2) with a Teflon pestle.  ~ 45 μl of the homogenate (H) was 
saved, solubilized with 1% SDS and clarified by centrifugation.  The remaining 
homogenate was centrifuged at 1,000 x g for 10 min to remove nuclei and incompletely 
homogenize material.  The pellet was discarded and the supernatant (S1) centrifuged at 
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10,000 x g for 15 min. The Pellet (P2) was suspended in 120 μl solution A, to which 960 
μl .5% Triton X-100 solution (10 mM Tris pH 7.4, 1 mM EDTA, 1mM EGTA) was 
added. This mixture was agitated at 4°C for 20 min and then centrifuged at 36,000 RPM 
for 20 min. The supernatant (S3) was saved and the pellet (P3) suspended in .5 ml 1 % 
Triton X-100 buffer (10 mM Tris pH 7.4, 1 mM EDTA, 1mM EGTA) by pipetting and 
probe sonication (three times for 5 seconds on low setting). The mixture was then 
agitated at 4°C for 30 min and centrifuged at 36,000 RPM for 30 min. The supernatant 
(S4) was saved and the pellet (P4), enriched for the PSD, was dissolved in 200 μl 20 mM 
Tris pH 7.4 with 1% SDS. All solutions were supplemented with 1 x protease and 
phosphate inhibitor cocktails (Sigma) as well as 1 mM sodium fluoride and sodium 
orthovanidate (Sigma). See Supplemental Figure 4-1 for a comparison of representative 
PSD and presynaptic protein enrichments from these preparations and those from Chapter 
3.  
Total protein amounts in all preparations were quantified with the micro BCA 
assay in duplicate (Pierce). Success of PSD enrichment was assessed post hoc by LC-
SRM/MS.   
3.3 Sample preparation and LC-SRM/MS: 
10 μg PSD enrichments and 20 μg whole tissue homogenate preparations were 
mixed with the [13C6] brain ISTD at a ratio of 1:1 (μg/μg) and processed for LC-SRM/MS 
analysis as described in Chapter 3, section 3.3, but with one difference. After separation 
on a 1.5 mm 4-12% Bis-Tris Gel (Invitrogen), the lane was divided into two fractions at 
the 64 kDa marker.  
 LC-SRM/MS was conducted as described in Chapter 3, section 3.4, with an 
expanded set of transitions. Subsequent to the experiments described in Chapter 3, 
additional data sets became available and additional proteins of interest were identified 
by parallel projects in the Hahn Lab. As of writing, peptide-SRMs for over 200 proteins 
have been validated.  The development of these additional SRMs drew upon the NIST 
and PeptideAtlas databases (Ref), along with a recent 2DLC-MS/MS analysis of mouse 
synaptic membrane enrichments performed in Dr. Steve Seeholzers laboratory (Seeholzer 
and Kalb unpublished). Human PSD enrichments and homogenates were first assayed for 
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a subset of these proteins. This subset included 127 synaptic proteins (Sup. Table 4-3, 
Appendix 2) that were either found to be enriched in the PSD (see Chapter 3) or are 
known to have postsynaptic roles. For example, a majority of G protein subunits was 
neither enriched nor un-enriched in PSD fractions, but are known to be active in 
postsynaptic processes (Ref).  A handful of presynaptic molecules were also included to 
assess purity of PSD enrichments.  The homogenate peptide preparations were also 
assayed in a separate LC-SRM/MS run for an additional set of 96 non-PSD neuronal 
proteins (Sup. Table 4-4, Appendix 2).  
3.5 Data processing, informatics and statistics 
LC-SRM/MS data was processed as described in Chapter 3, section 3.7, as was 
calculation of protein amount and protein enrichment values.  
Success of biochemical fractionation was assessed by investigation of enrichment 
values for the PSD proteins NR1, PSD95 and CaMKIIα, as well as the SNARE complex 
proteins synapsin 2, syntaxin 1B, syntaxin binding protein and synaptobrevin (VAMP).  
Subjects for which the two of three PSD protein enrichment values were below 2 and/or 
two of the four SNARE complex enrichment values were at or above 1 were dropped 
from analysis (calculations not shown).  
Three types of data sets were generated from LC-SRM/MS analyses of human and 
rhesus monkey PFC preparations: 1) Protein measures in total homogenate preparations, 
2) Protein measures in PSD fractions, and 3) Protein enrichment values.  Total 
homogenate protein measures were normalized to beta tubulin. The rationale for this 
choice and the associated caveats are considered in section 5.2 of the discussion. PSD 
protein measures were normalized over PSD95 to assess the relative ratios of core PSD 
proteins.  As in Chapter 3, section 3.7, protein enrichment values were the [PSD protein 
measures] / [total homogenate protein measures] without the introduction of an additional 
normalization factor.  
Outlier subjects or animals were identified by manual inspection for the number of 
individual protein or enrichment value outliers and principle component analysis of the 
entire dataset, run as a plug-in in Excel.  Normalized protein or enrichment value outliers 
were defined as > [(Group Mean) + (2 * standard deviation)].  Principle component 
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outliers were defined as a subject or animal having two (or more) vector values greater 
than two standard deviations away from the vector mean. In the event that a subject or 
animal was identified as an outlier by either of these methods, it was only dropped from 
analysis provided that its absence did not affect the assignment of significance in all data 
analyses (calculations not shown).  
The enrichment and expression datasets were processed in a similar fashion:  To 
begin, the average of protein measures (or protein enrichment values) for each group 
(SCZ and CTL) were calculated in Excel, and the distribution of these averages plotted in 
GraphPad Prism 5. The ratio of the SCZ average over the control average (SCZ/CTL) 
was calculated for each protein, and the distribution of these ratios plotted.   The 
distribution shape range, mean and median was considered in evaluation of the dataset 
and evaluation of normalizing factors. As a preliminary evaluation, two-tailed Students t-
test was used to assign P-values to individual proteins for between-group differences 
(SCZ vs CTL). Proteins were then ranked by P-value. Proteins with a P-value < .2 were 
identified and divided into two groups based by SCZ/CTL ratio: > 1 and < 1.  The ranked 
protein lists were then submitted, as a list of official gene symbols, to the DAVID 
Functional Annotation Tool, and searched for Kegg pathway and gene ontology (GO) 
term enrichment. The full list of quantified proteins, submitted as non-redundant 
International Protein Index (IPI) identification numbers, served as the background.  The 
results of this analysis were used to inform the grouping of proteins by direction of 
regulation and functional annotation for further analysis. Two-way ANOVA in GraphPad 
Prism 5 was used to assign significance of diagnosis (human) or drug (rhesus monkey) 
effect on protein measures or enrichment values for identified protein groups. 
Considering the relatively loose criteria used to group the proteins and the propensity for 
Type I errors in postmortem experiments, a Bonferroni correction was employed in 
assigning diagnosis or drug effect significance to grouped protein values.  17 two-way 
ANOVAs were run on data from experiments in humans and 17 on data from 
experiments in rhesus monkeys, so P-values for assigning significance were set at .0029 
(.05/17). P-values determined by T-test for individual protein regulation are reported, but 
are not discussed in terms of significance.  
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 Correlations between subject PMI, age and significantly regulated protein values 
were assessed in GraphPad Prism 5. Only the subset of data generated from rhesus 
monkey tissue experiments, required to control for neuroleptic drug effects, are reported 
here.  
Unsupervised hierarchical clustering was performed on a manually selected 
subset of non-normalized protein values from human total homogenates, human PSD 
enrichments and rhesus monkey PSD enrichments as described in Chapter 3, section 3.7.  
4. Results 
4.1 Protein levels in whole tissue homogenates 
223 proteins were quantified in whole tissue homogenates derived from the LPFC 
of 15 SCZ subjects and matched controls. Of these, 185 met the criteria described in 
Chapter 3 for inclusion in analysis (Sup. Table 4-5, Appendix 2).  Sample #2 (batch 1) 
showed inconstancies in HPLC; irregular peptide retention times were observed despite 
retiming of the method and multiple LC-SRM/MS runs, requiring the exclusion of 
sample #2 from analysis.  
Initial analysis began with plotting distributions of average beta tubulin-
normalized protein values for each group (SCZ and CTL). Distribution of average 
normalized protein values was highly similar between SCZ and control (Sup. Figure 4-2 
A&D). Next the ratio of these averages (SCZ/CTL) was taken and the distribution of 
these values plotted. The ratios (SCZ/CTL) of average normalized expression values fell 
over a normal distribution, ranging from .5 to 1.3 with a median and mean of 1.03 (Figure 
4-2A).   Of these, twelve were up-regulated in SCZ with a P < .2 (Figure 4-2D). Proteins 
with the GO terms macromolecule catabolic process (GO:0009057 P = .004) and protein 
amino acid autophosphorylation (GO:0046777, P = .0015), were significantly enriched 
against a background of 185 IPI entries. Based on this analysis and a manual inspection 
of these data the regulation of all assayed members of the CaMKII family (α, β, δ and γ) 
were assessed as a group by two-way ANOVA as were ubiquitin enzymes and 
proteasome subunits.  CaMKIIs were significantly increased as a group (P = .0002, 
Figure 4-2B), as were the proteolysis pathway enzymes proteasome subunit alpha-1  
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(PSMA1), E3 ubiquitin-protein ligase (UBR4), ubiquitin isopeptidase T (USP5) and 
ubiquitin carboxyl-terminal esterase L1 (UCH-L1) (P = .0012, Figure 4-2C).    
To control for antipsychotic drug effects, the expression of these proteins was 
assessed in total homogenate fractions from rhesus monkeys treated with clozapine, low 
haloperidol, high haloperidol or vehicle for six months. While CaMKIIδ was significantly 
up-regulated by both doses of haloperidol, none of the antipsychotics induced the broad 
Figure 4-2. Differentially expressed proteins in the schizophrenic LPFC. Quantitative 
measures of 222 proteins, normalized to beta tubulin, were assessed in whole tissue 
homogenates prepared from the LPFC of 15 schizophrenic subjects and matched controls and 
rhesus monkeys treated with neuroleptics. The average protein measure was taken for each 
group and the schizophrenia average divided by the control average (SCZ/CTL) to obtain a 
ratio of dysregulation for each protein. A, shows the distribution of these dysregulation ratios. 
The tight normal distribution about the mean/median (1.03) is reflective of the low number of 
different protein levels between the two groups. D, lists the proteins whose between group 
difference has a P-value < .2. P = P-value, two-tails T-test, SCZ/CTL = average 
schizophrenia protein value / average control protein value, OGS = Official Gene Symbol. B 
and C, show average normalized values for CaMKII (B) and proteolytic (C) proteins in 
human samples, while E and F, show the same values in tissues from rhesus monkeys. CTL = 
control subjects, SCZ = schizophrenia, Veh = vehicle, Cloz = , L Hal = low dose haloperidol 
and H Hal = high dose haloperidol. Error bars are standard error of the mean.  
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increase of CaMKII proteins observed in SCZ tissue (Figure 4-2E).  Antipsychotic drug 
treatment had a significant effect on proteasome pathway protein levels (P = .0002). Both 
clozapine and high haloperidol induced a small increase in PSMA1 and USP5 levels. 
High haloperidol induced a greater up-regulation of USP5, as compared to other 
regulations observed in this group. Neither PMI nor age correlated with amounts of these 
proteins in human tissue (Sup. Figure 4-5).   
4.2 PSD protein enrichment  
Enrichments from 9 control and 8 SCZ subjects, representing 8 pairs and one 
orphan control subject from batches 2 and 3, and all enrichments from rhesus monkey 
tissue met the criteria for inclusion described above. 107 synaptic proteins were 
quantified in these PSD preparations (Sup. Table 4-3, Appendix 2). Enrichment values 
for 104 of the synaptic proteins were calculated (Sup. Table 4-6, Appendix 2).  In light of 
potential confounds due to the different protocols used to enrich PSD fractions in batches 
2 and 3, data analysis was performed on the six pairs from batch 3 as a stand-alone data 
set (referred to henceforth as “6 pairs”) and on batches 2 and 3 together (referred to 
henceforth as “9 pairs”). Batch 2 consisted of only three pairs, lacking the statistical 
power to be considered alone. 
 Principle component analysis did not identify any subject or animal as an outlier 
(data not shown), but enrichment values for the majority of PSD proteins in sample #22 
were outliers when considered in the context of 9 pairs, but not of 6 pairs.  The removal 
of this sample (#22) from the 9 pairs dataset did not alter the statistical outcome of any of 
the analyses detailed below. For these reasons, sample #22 was dropped from the 9 pairs 
analysis. 
The ratio (SCZ/CTL) of average enrichment values for 6 pairs ranged from .23 to 
1.64 in a graphical shape suggesting an asymmetrical bimodal distribution (Sup Figure 4-
3A).  The median and mean were 1.05. Of the 6 pairs enrichment values, 22 were 
elevated and 10 were decreased in SCZ as compared to controls with a P < .2 (Sup.  
Tables 4-2A & B).  The ratio (SCZ/CTL) of average enrichment values for 9 pairs fell 
over a more symmetrical distribution than that of 6 pairs, ranging from .44 to 2.07 with a 
median and mean of 1.3 (Sup. Figure 4-3C). Of the 9 pairs enrichment values, 29 had 
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elevated enrichment values and 2 had depressed enrichment values with a P < .2 (Sup. 
Figure 4-2C & D). Lists of elevated proteins from both data sets include glutamate 
receptors, kinases and voltage-dependent anion channels, along with the occasional 
Figure 4-3. Enrichment, but not amount, of postsynaptic glutamate receptors and 
scaffolding proteins is altered in the LPFC of schizophrenia subjects.  Biochemical 
fractions enriched for PSDs were prepared from the LPFC of 9 schizophrenic subjects and 
matched control and rhesus monkeys treated with different neuroleptics. Quantitative 
measures of 107 proteins were aszsayed therein by LC-SRM/MS. Enrichment values for 104 
of these proteins were calculated by divideing un-normalized protein measures in PSD 
enrichments by un-normalized protein measures in whole cell homogenates. A, shows average 
beta tubulin-normalized protein measures from 15 pairs of human tissue. PSD protein levels, 
as a group, were not significantly impacted by diagnosis (P = .16), but NR2B did show a trend 
upward (P = .07). B, shows average protein enrichment values from 9 pairs of human tissue, 
which were significantly increased in PSD preparations from disease tissue, with average 
increase of 35% above control (P < .0001). C, shows average beta tubulin-normalized protein 
measures from rhesus monkey tissues. PSD protein levels, as a group, were not significantly 
impacted by neuroleptic treatment (P = .65), but NR1 was significantly decreased in H Hal (P 
= .03). D, shows average protein enrichment values from rhesus monkey tissues, which were 
significantly decreased by H Hal (P = .0076). Error bars are standard error of the mean. CTL = 
control, SCZ = schizophrenia, Veh = vehicle, and H Hal = high dose haloperidol 
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scaffolding protein.  Notably, both lists include all AMPA and NR subunits assayed (Sup. 
Tables 4-2 A & C). Proteins that were decreased in the 6 pairs included G-protein 
subunits (GNB1, GNAs and GNAi1), protein phosphatases (PPP1R7 and PPP2R1A) and 
SNARE complex proteins (SYN2, STX1B and STXBP1) (Sup Table 4-2 B). Pathway 
analysis in DAVID indicated that the group of proteins with enhanced PSD enrichment in 
SCZ patients (in the 9 pair cohort) was enriched for the functional annotation 
Figure 4-4. Relative 
amounts of PSD proteins 
are similar in PSD 
enrichments from LPFCs 
of control and SCZ 
subjects. Biochemical 
fractions enriched for PSDs 
were prepared from the 
LPFC of 9 schizophrenic 
subjects and matched 
controls and rhesus monkeys 
treated with different 
neuroleptics and assayed by 
LC-SRM/MS. Quantitative 
measures of core PSD 
proteins were normalized to 
PSD95. A, shows average 
PSD95-normalized protein 
measures from human PSD 
enrichments. PSD protein 
levels, as a group, were not 
significantly impacted by 
diagnosis, but SAP97 did 
show a trend downward (P = 
.08).  B, shows average 
PSD95-normalized protein 
measures from rhesus 
monkey PSD enrichments. 
The high dose of haloperidol 
(H Hal) induced significant 
changes to PSD protein 
levels (P < .0001). Error bars 
are standard error of the 
mean. CTL = control, SCZ = 
schizophrenia, Veh = 
vehicle, and H Hal = high 
dose haloperidol  
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postsynaptic cell membrane (P = .0007).   
Based on the preliminary analysis described above, biochemical enrichment 
values for postsynaptic glutamate receptors, scaffolding proteins and voltage-dependent 
cation channels were considered as a group. In analyses of both cohorts, diagnosis 
significantly impacted protein enrichment values (6 Pairs: P < .0001, 9 Pairs: P = .0003), 
all of which were elevated in PSD preparations from SCZ subjects, as compared to 
control subjects (Sup. Figure 4-3 D, Figure 4-3 B). Beta tubulin-normalized levels of 
these proteins in total homogenates were not significantly increased in SCZ patients in 
any of the three batches alone in combinations of batches (Figure 4-3A, 15 pairs), 
although NR2B did show a slight increase with and individual P-value of .07.   
 To determine if neuroleptic treatment could contribute to the observed increase in 
PSD protein enrichment, the impact of antipsychotic drug treatment on amount and 
enrichment of these PSD proteins in rhesus monkeys was assessed. Glutamate receptor 
and scaffolding protein amounts were unaffected by neuroleptics in whole tissue extracts 
(clozapine and low haloperidol data not shown; for high haloperidol see Figure 4-3C). 
Voltage-dependent cation channel expression was decreased in all three antipsychotic 
treatment groups (P = .0005; independent group analysis not shown). In stark contrast to 
alterations seen in postmortem tissue of SCZ patients, high dose haloperidol decreased 
the enrichment values of 12 out of 15 postsynaptic proteins in PSD preparations (P = < 
.0001, Figure 4-3D). Enrichment of VDAC3 was increased while NR2A and GRIM5 
were unchanged.  Clozapine and low haloperidol treatment did not result in altered 
enrichment of these proteins (data not shown).   
 Enrichment values for five additional manually configured protein groups were 
also investigated in PSD preparations from both human and rhesus monkey tissue. No 
significant differences were observed between disease and control preparations, while 
neuroleptics induced diverse and complicated changes.  Enrichment of protein 
phosphatases, presynaptic proteins and septins were unchanged, ankyrins and spectrins 
were decreased (P = .0004) and neuronal adhesion molecules were increased by low dose 
haloperidol, while the high dose haloperidol animals showed either no change or a 
possible decrease (Sup. Figure 4-4). 
76 
 
 Finally, PMI and age did not correlate with enrichment values for PSD or SNARE 
complex proteins (see supplementary figure 4-6 for representative histograms).    
4.3 Relative amounts of core PSD proteins     
 To compare relative amounts of core PSD proteins in PSD enrichments, protein 
measures were normalized to PSD95 measures.  No outlying subjects or animals were 
identified in this dataset. PSD95-normalized values for postsynaptic glutamate receptors, 
scaffolding proteins, kinases and voltage-dependent anion channels were compared in 9 
pairs. The relative amounts of these proteins were nearly identical (Figure 4-4A), with the 
exception of SAP97, which trended down in the disease group (P = .083).  No changes 
were seen in the clozapine and low haloperidol groups (data not shown), while high 
haloperidol significantly regulated PSD95-normalized values, inducing changes in both 
directions between the two groups (P < .0001, Figure 4-4B). PMI and age did not 
correlate with PSD95 normalized values of these proteins (Data not shown).  
4.4 Unsupervised hierarchical clustering     
Unsupervised hierarchical clustering was used to investigate whether relative 
protein composition could distinguish between disease and control PSD enrichments.  
Clustering analysis was performed using non-normalized values of selected proteins from 
6 pairs. The full 9 pairs could not be used, as the clustering analysis was sensitive to the 
different enrichment protocols. The analysis returned a striking separation of disease and 
control subjects (Figure 4-5A), with only one individual “incorrectly” placed out of each 
group.  An identical analysis of non-normalized values for the same proteins from whole 
cell homogenates was unable to distinguish between disease and control (Figure 4-5B). 
Interestingly, the segregation of PSD enrichments into two “correct” groupings appears to 
be driven not by core PSD proteins, but by a diverse group of protein phosphates, 
presynaptic proteins, GAD65, ankyrins and brain creatine kinase  (Sup. Figure 7A).  This 
constellation of relative changes in SCZ contrasts with clustering of vehicle and high 
dose haloperidol samples, in which parsing of animals is driven by relative differences 
between the core PSD proteins (Figure 4-5C, Sup Figure 4-7C). Thus, although PSD 
enrichments from disease subjects and haloperidol treated animals differ significantly
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 from their respective controls, the nature of this dysregulation is fundamentally 
dissimilar.  
5. Discussion 
In this study biochemical fractionation was combined with a quantitative and 
targeted proteomics approach to evaluate synaptic protein expression and partitioning in 
the LPFC of SCZ. 185 proteins were quantified in whole tissue homogenates prepared 
from 15 pairs of SCZ subjects and matched controls. 107 proteins were quantified in PSD 
enrichments from 9 pairs. This approach yielded a data set with the statistical power to 
make several highly significant observations.  The power of this approach also allows for 
increased confidence in null results (the finding of few differences in protein expression 
between SCZ and controls). Four observations 
were made in these experiments: 1) The vast 
majority of normalized protein levels was 
unaltered in disease tissue, with the exception 
of small (20%) but significant increases in 
Figure 4-5. Hierarchical clustering separates 
subjects by diagnosis based on protein levels 
in PSD enrichments but not total 
homogenates. A. Unsupervised hierarchical 
clustering, with Pearson's Correlation as the 
similarity metric, was utilized to group subjects 
and selected PSD proteins by non-normalized 
protein values measured in PSD enrichments. 
SCZ and control were segregated into two groups 
with one exception. C = control, S = 
schizophrenia. B, shows an identical analysis of 
the same subjects and proteins using non-
normalized protein values measured in whole 
tissue homogenates. C = control, S = 
schizophrenia. C, shows an identical analysis of 
the same subjects and proteins using non-
normalized protein values measured in PSD 
enrichments from rhesus monkeys. V = vehicle, 
HH = high does haloperidol. The open and 
closed circles were added to enhance visual 
contrast between the two groups in each analysis. 
For an expanded version of these heat maps, with 
protein annotations, see supplemental Figure 4-7.  
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CAMKII and proteolytic pathway proteins (Figure 4-2). 2) PSD glutamate receptors, 
scaffolding proteins and voltage-dependent cation channels were, on average, 40% more 
enriched in PSD preparations from the tissue of SCZ subjects as compared to control 
subjects (Figure 4-3), while the enrichment of ten other proteins group was unaltered. 3) 
Despite the enrichment differences, amounts of postsynaptic glutamate receptors, 
scaffolding proteins, voltage-dependent cation channels and kinases, normalized to 
PSD95, were nearly identical in PSD enrichments from the two groups (Figure 4-4). 4) 
The protein composition of PSD enrichments from SCZ samples was sufficiently 
different to allow for unsupervised hierarchal clustering to parse disease and control 
subjects with striking accuracy, using non-normalized protein values.  These four 
observations strongly support the conclusion that partitioning, not expression, of PSD 
complex proteins is the major molecular correlate of decreased spine density in the LPFC 
of SCZ. However, several caveats need to be addressed to increase confidence in these 
findings. These caveats are addressed in the next section, before further discussion of the 
findings.  
5.1 Planned experiments to address experimental caveats   
1. Expanding human and rhesus monkey cohorts: Replicating these findings in an 
expanded cohort is essential. First, a minimum of 12 additional pairs, prepared in two 
batches of 6 using the abridged protocol, will be assayed and the samples from batch 2 
removed from future analysis. This will result in a final N of at least 18 per group, with 
all samples prepared by an identical protocol.  Additionally, the rhesus monkey cohort 
generously provided by Dr. Scott Hemby contains 19 more female animals, doubling the 
N for all groups. These animals will be prepared and analyzed as well.  
2. Increasing options for normalization of protein expression: A constant concern 
with any expression study, in regards determining total protein levels in a given 
biological sample, is the choice of a loading control. Beta tubulin 3 is often the protein of 
choice for normalization in brain tissue. It is often used in protein and mRNA expression 
studies in human and animal brain tissue173. Indeed, a recent study of SCZ tissues with 
similar cytoarchitectural deficits utilized beta tubulin, concluding that it is unaltered in 
disease174. Additionally, multiple proteins and combinations of proteins were evaluated as 
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potential normalizing factors post hoc, all of them returning similar results. Indeed, 
relative sample-to-sample difference in protein value for the majority of the 185 proteins 
quantified mirrored beta tubulin, as is evidenced by the tight distribution of normalized 
protein values centered at a median/mean of 1.03 (Figure 4-2A). Finally, within our data 
set, there was no protein in the distribution’s higher ranges whose use as a normalizing 
factor could be biologically justified. These arguments must be balanced against two 
points: 1) Beta tubulin is a major structural component of axons and dendrites and several 
groups have reported decreased volume and dendrite length of pyramidal neurons in 
additional to spine loss in the DLPFC. Although, these decreases are not as large or 
significant as, and do not consistently correlate with, decreased spine density.  
Nevertheless, considering decreased neuron volume and dendrite length, decreased 
amounts of beta tubulin could mirror decreased pre- and post-synaptic proteins levels, if 
present. 2) The list of proteins assayed is, by design, rich in synaptic molecules, limiting 
the choices for a non-synaptic normalizer and potentially masking disease effects on the 
entire field. To more thoroughly address this potential confound, future analyses will 
include peptide SRMs for multiple nuclear, glial and astrocyte markers, even though the 
use of these proteins would carry its own caveats. For example, a [synaptic]/[nuclear] 
protein normalization would most likely be confounded by projections from other brain 
regions. Still, the inspection of this dataset from multiple extra-synaptic normalization 
perspectives will likely provide additional valuable information. 
3. Additional controls for postmortem interval: The studies modeling postmortem 
interval described in Chapter 3 were performed using the full protocol detailed in that 
chapter. To thoroughly control for PMI confounds, this experiment will be repeated using 
the abridged enrichment protocol used to prepare batch 3.  
4. Enrichment variability: Accuracy and precision of the LC-SRM/MS assay was 
rigorously validated at several steps in the protocol and validation of the biochemical 
fractionation protocol by traditional methods (electron microscopy, Western blot) has 
been peer reviewed. However, assessment of fractionation reproducibility from the same 
tissue sample by LC-SRM/MS has not been performed. This omission must be addressed, 
to complete assessment of method variability at every step of the protocol.   
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5. Bioinformatics: The informatics and statistical methods applied here identified protein 
groups with expression and enrichment values significantly regulated by diagnosis or 
drug treatment.  A conservative bar for reaching statistical significance was set to guard 
against type I Errors. Due to the testing of multiple hypotheses and dataset complexity, 
this analysis should be considered a first step analysis until a more in-depth and rigorous 
model can be applied with proper consultation. Ongoing informatics analysis will include 
assessment of interactions between proteins across 
tissue preparations and in the context of protein 
interaction and cellular compartment annotations. 
Indeed there are several interesting patterns, discussed 
in final Chapter, that hint at deeper findings buried 
within this dataset.  
5.2 Interpretation of current dataset: A 
novel hypothesis for the relationship between 
PSD proteins and spine density in 
schizophrenia 
Decreases in dendritic spine density have been 
observed in layers 2 and 3 of the DLPFC in SCZ35, 43.  
It logically follows that the levels of proteins that 
compose spine PSDs would be decreased as well. The 
results of this study, however, are not consistent with 
that prediction. Instead, these data suggest that neurons 
with decreased spine density, compared to controls, 
have the same amounts of PSD proteins, compared to 
controls. In this scenario, dendritic spines could contain 
more PSD protein, an assertion supported by my data. 
PSD enrichments prepared from SCZ subjects were 
more enriched for PSD proteins, while the enrichment 
of other protein groups was unaltered.  Additionally, I 
observed that the relative amounts of PSD complex 
Figure 4-6. Possible 
configurations of spines and 
PSDs in schizophrenia. A, 
depicts the “normal” 
distribution of PSD complexes 
in dendritic spines. B. and C. 
show two alternate PSD 
complex distributions in which 
PSD protein expression is 
unaltered and spine density is 
decreased in SCZ. B. PSD 
protein levels, per spine, are 
increased. C. “extra” PSD 
complexes are present in 
dendritic shafts and are 
enriched along with spine 
localized PSD complexes in 
biochemical preparations.  
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members are highly similar between SCZ and control subjects. This suggests that while 
the amount of PSD complexes at remaining dendrites maybe increased in SCZ, the 
relative protein composition of these PSD complexes is unperturbed.  Interestingly, 
decreased spine density, but increased spine size, has been observed the cortex of 
pyramidal neuron NR1 -/- mice 93, suggesting that inhibition of NR function could 
increase the amount of PSD proteins at dendritic spines. In an alternate scenario, the 
amount of PSD proteins in remaining spines would be unaltered. Instead the “extra” PSD 
complexes could exist as lipid rafts175, 176, in the dendritic shaft. These scenarios are 
depicted in Figure 4-6. There is however one potential caveat to both of these 
interpretations.  
 While this study has excellent precision and some spatial resolution at the PSD 
microdomain, it was still conducted in a whole LPFC section. Thus differences in 
synaptic protein expression confined to discreet cortical layers or neuronal subtypes 
could still be lost in the complexity of a LPFC homogenate.  Given that limitation, the 
consistent increased enrichment of all core PSD proteins in SCZ in this tissue implies that 
this perturbation is either widespread in the cortex or a large effect confined to a specific 
neuronal population.   
 In addition to the caveats discussed above in section 5.2, three experiments are 
essential to flesh out the implications of these findings. 1) Laser capture of discreet 
DLPFC cortical layers followed by LC-SRM/MS to quantify layer specific protein levels 
would be ideal to confirm or refute the lack of observed differences in protein expression. 
The feasibility of this experiment is discussed in Chapter 5. 2) While these findings 
suggest that decreased spine density is correlated with increase enrichment of PSD 
proteins they do not prove it.  Spine density and PSD protein enrichment will need to be 
assessed in the same DLPFC tissues of SCZ subjects to determine if such correlation 
exists. Encouragingly, a similar experiment, in which decreased spine density was 
significantly correlated with decreased septin7 mRNA levels, has been successfully 
conducted177.  3) Tissue tomography or electron microscopy, with immuno-gold against 
PSD-95, in postmortem tissue will be essential for both confirming that the ratio of PSD 
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complexes to spines is increased in SCZ and for determining the location of these 
complexes.   
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CHAPTER FIVE  
CONCLUDING THOUGHTS AND FUTURE 
DIRECTIONS 
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The goal of this thesis work was to develop a fractionation - mass spectrometry 
approach for the quantification of synaptic proteins in human postmortem brain tissue 
and apply this approach to the study of synaptic protein expression and PSD partitioning 
in the LPFC of SCZ patients.  To that end I performed a 2DLC-MS/MS analysis of PSD 
enrichments prepared from human postmortem LPFC. The resulting peptide spectral 
library, and ones like it, were used to develop an LC-SRM/MS assay for the multiplexed 
quantification of peptide SRMs from over 200 synaptic proteins. These peptide SRMs 
were rigorously validated for fidelity, accuracy and precision in peptide/protein 
quantification. The LC-SRM/MS assay was then used to further validate biochemical 
fractionation protocols for the enrichment of synaptic microdomains in human 
postmortem brain tissue, demonstrating that subcellular fractions prepared from human 
postmortem brain tissue were strikingly similar to those prepared from fresh mouse brain 
tissue. Finally, this fractionation – LC-SRM/MS approach was used to quantify close to 
200 proteins in whole tissue homogenates prepared from the LPFC of 15 pairs of SCZ 
and matched controls subjects and 107 proteins in PSD enrichments prepared from the 
LPFC of 9 SCZ and matched control subjects.  A preliminary interpretation of the data 
from this final experiment strongly suggests that partitioning, not expression, of PSD 
proteins is altered in the LPFC of SCZ patients.  Based on these results, I have proposed 
two possible models to explain how PSD protein expression in the SCZ DLPFC could be 
unaltered while dendritic spine density is decreased (Figure 4-6). Additionally, a list of 
future experiments is included here, which could be utilized to confirm this finding and 
investigate the accuracy of the two proposed models. This work demonstrates the 
feasibility and power of combining biochemical methods with a targeted MS proteomics 
approach to address a specific question in biology.   
As noted previously, comparisons of core PSD proteins, normalized by PSD95, 
found PSD complex composition to be highly similar between SCZ and control. 
Interestingly, however, when one compares the difference between the average PSD95-
normalized values for SCZ over control, the size of that difference appears to be related 
to the distance between that protein and the PSD in the synapse.  That is, the “farther 
away” a protein is from the PSD in the synapse, the greater the disparity in that proteins 
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PSD95-normalized value between SCZ and control (Figure 5-1).  It is possible that this 
pattern reflects alterations in the distribution of PSDs throughout the dendrite in SCZ. 
Alternatively, these differences could reflect a dysregulation in the interaction between 
the PSD and adjacent microdomains.    
The findings reported in Chapter 4 dealt almost exclusively with the increased 
enrichment of PSD proteins as a group in SCZ. While these findings provide some 
insight into 
the 
distribution 
of PSD 
complexes in 
the dendrites 
of SCZ 
subjects, they 
do not 
address 
alterations to 
PSD 
complex 
protein 
composition 
that could 
correlate with 
NR 
hypofunction. 
While 
significant differences between disease and control enrichments were observed in the 
PSD95 normalized dataset, the differences in enrichment, discussed in the last paragraph, 
must be taken into consideration to interpret these data. The sections below discuss the 
next challenges in quantitative proteomics in study of human postmortem brain tissue as 
Figure 5-1. PSD95 normalized protein values may be related to 
postsynaptic density proximity.  PSD95 normalized values were 
calculated for proteins measured in PSD enrichments from 9 pairs. The 
average value for each protein in the SCZ and control groups was taken and 
the percent difference ([Control/SCZ)] * 100) between the two groups 
calculated for each protein.  The percent differences were then given a sign 
depending on assumed location in the synapse (- for postsynaptic, + for 
presynaptic), plotted in one dimension and color coded by functional.  
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well as in the interpretation of protein data from synaptic microdomain enrichments. 
Selected findings in PSD protein composition and activity will also be presented to 
illustrate complications in data interpretation. 
1. Proteomics in neuroscience  
This study represents a first step towards bringing a targeted proteomic approach to 
bear on the study of neuropsychiatric illness in human postmortem brain tissue. 
Proteomics investigations can be configured in a variety of ways to achieve numerous 
goals. Already, a number of different strategies have been employed to assay 
phosphorylation, ubiquitination, nitrosylation and glycosylation events60, 109, 178, 179. In 
that vein it is my sincere hope that the neuroscience community here at the University of 
Pennsylvania and beyond will utilize and expand upon the method developed as part of 
this work to address a variety of questions in the field of neuroscience.  
1.1 Layer- or cell type - specific protein quantification in postmortem 
studies. 
The strategy developed in this thesis has spatial resolution for synaptic microdomains 
but not neuronal subtypes or cortical layers. Thus the data generated here allow for the 
possibility that PSD protein expression is altered in a specific neuronal population (e.g. 
interneurons) or cortical layer; the signal for this alteration lost in the noise of a tissue 
homogenate. Furthermore, these data provide little insight into the cell population driving 
increased PSD protein enrichment or if these “extra” PSD proteins are localized to 
dendrites or elsewhere in the neuron. As previously noted, immunohistochemistry, tissue 
tomography and electron microscopy studies will be essential for addressing these 
questions. However, these approaches are unable to assay changes to synaptic protein 
expression and partitioning in a multiplexed fashion. Thus, adapting the targeted method 
developed here to the quantification of protein extracts from specific neuronal 
populations or cortical layers is highly desirable.  MS proteomics methodologies have 
been used to profile proteins in single-cell type populations isolated by flow cytometry180 
and laser capture181. Indeed laser capture – proteomics has been used to profile cortical 
lewy bodies182 and hippocampal neurofibrillary tangles183 from human postmortem brain 
tissue.  Laser-capture – qPCR has been utilized to quantify mRNA expression in a 
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number of cell 
types in human 
postmortem 
tissues from SCZ 
and bipolar 
patients107 184 106.  
Thus, a laser-
capture – 
proteomics 
approach could be 
able to quantify 
protein amounts in 
discrete cortical 
layers.   
The use of 
LC-SRM/MS, 
with [13C6]-brain 
ISTD, has several 
advantages over 
LC-MS/MS 
strategies. One 
advantage is the 
low protein 
requirement necessary for utilization of this method. The experiments described in 
Chapter 4 utilized only 10-20 μg of total protein for preparation, with 10-25% of this 
preparation analyzed in one LC-SRM/MS run. In method development experiments 
conducted at a ThermoScientific demonstration laboratory (Somerset, NJ) with Dr. Gene 
Ciccimaro, we successfully monitored PSD protein peptides, at quantitative intensities, in 
as little as 90 ng of peptide injections. An additional benefit of the LC-SRM/MS method 
is the [13C6]-brain ISTD which serves as a carrier in addition to its capacity as an internal 
Figure 5-2. Three different perspectives of PSD protein 
composition in schizophrenia.  Three different normalizations for 
select proteins measured in PSD enrichments from 6 pairs of SCZ and 
matched controls. A. shows fold enrichment values, B. protein values 
normalized to beta tubulin values and D. protein values normalized to 
PSD95. C. LPFC slices from 8 pairs of SCZ and control subjects were 
stimulated with 1μM (RS)-2-chloro-5-hydroxyphenylglycine  (CHPG). 
mGluR5- Gprotein subunit alpha q interaction and mGluR5-  
phosphorylation was quantified by Co-IP and Western blot after 
stimulation and at baseline. C, shows the fold induction (stimulated 
/baseline) measure for mGluR5 phosphorylation and G-protein 
interaction. Note that CHPG induction of phosphorylation, de-
phosphorylation and G-protein release is attenuated in SCZ tissues, 
suggesting that mGluR5 activity is perturbed.  
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standard. Thus, in a theoretical laser capture experiment, isolated cortical layers could be 
collected in a solution containing an excess of the [13C6]-brain ISTD, SDS and reducing 
agents. While the optimization and validation of such a protocol would likely be a 
significant endeavor, it should be possible utilize LC-SRM/MS with the [13C6]-brain 
ISTD for quantification of synaptic proteins in cortical layers isolated by laser capture. 
2. Controlling for enrichment confounds in microdomain protein 
quantification 
Our findings of altered PSD enrichment complicate investigation of the PSD 
microdomain in SCZ.  Specifically, investigations into altered PSD protein complex 
composition must be considered in the context of increased postsynaptic protein 
enrichment, lest differences in protein enrichment between SCZ and control tissue be 
falsely interpreted as altered trafficking to, or interactions at the PSD. An example is used 
to further explain this point: 
In Figure 5-2, the levels of six proteins in PSD enrichments from 6 pairs are 
considered. The amounts of these proteins, measured in PSD enrichments, are viewed 
from three different perspectives: First, as enrichment values (5-2A), next as beta tubulin-
normalized protein values (5-2B) and finally as PSD95 normalized-protein values (5-2D).  
If these data are viewed from the perspective of beta tubulin (TUBB) normalization, 
without taking into account the differences in enrichment, one might conclude that the 
amounts of all proteins are increased in the SCZ group. Considering the variations in 
enrichment differences between proteins (5-2A), this interpretation would likely be 
incorrect. Alternatively, PSD95-normalization (5-2D) likely paints a more accurate 
picture of relative protein differences within the PSD complex, but the results must still 
be interpreted with caution. PSD95 normalized values for mGluR5 (GRM5) and Gq 
alpha (GNAQ) are significantly decreased in PSD enrichments from SCZ subjects (P = 
.004 and .03). However, mGluR5 shows the increased enrichment in SCZ shared by the 
core PSD proteins PSD95 (DLG4) and GKAP1, while Gq alpha enrichment values 
between SCZ and control are highly similar.  Thus, one might conclude that the mGluR5 
decrease represents dysregulated protein composition “within” the PSD microdomain, 
while decreased PSD95-normalized Gq alpha values reflect a fundamental disconnect, 
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perhaps in space or in microdomain interaction, between the PSD and its surroundings. It 
should be noted that this an example of only 6 out of over 100 proteins, used to illustrate 
confounds that should be considered when analyzing quantitative data in a microdomain 
enrichment. Going forward a more rigorous statistical consideration of these confounds 
must be made.  
 As a finally note, it should be mentioned that despite the complexities associated 
with interpreting this dataset, this example did provide useful information. Both this 
experiment and another performed previously on PSD enrichments from a similar cohort 
(not discussed here) observed decreased PSD95-normalized mGluR5 levels in PSD 
enrichments from SCZ subjects. We hypothesized that this decrease may correlate with 
perturbed mGluR5 activity. To investigate this, DLPFC tissue from 8 pairs of SCZ and 
matched control tissues were sent to Dr. Hoau-Yan Wang, where ex-vivo stimulation 
experiments revealed decreased mGluR5 activity, as measured by receptor 
phosphorylation and G alpha q subunit release (Figure 5-2C). This final experiment 
demonstrates the promise of the fractionation – LC-SRM/MS approach in assessing 
altered protein expression and partitioning events that may be reflective of function 
deficits at the synapse in SCZ. 
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Table 2-1. Peptide identifications were confirmed by inspection of MS2 spectra and 
targeted MS2 analysis of peptide parent masses. Description: IPI identifier. % Cov:  
Percent of protein sequence covered by observed peptides. 
% Protein IPI
Description Cov Probability Accession 
1 Adaptor-related protein complex 40 1.00 IPI00619900
2 ADP-ribosylation factor GTPase-activating protein 1 29 1.00 IPI00175169
3 A-kinase anchor protein 12 22 1.00 IPI00867627
4 A-kinase anchor protein 5 18 1.00 IPI00307794
5 BR serine/threonine protein kinase 1 15 1.00 IPI00148020
6 Brain Creatine Kinase 72 1.00 IPI00022977
7 Calmodulin 47 1.00 IPI00075248
8 Calpain 1 20 1.00 IPI00025084
9 CAMKII Alpha 43 1.00 IPI00877169
10 CAMKII Beta 40 1.00 IPI00334271
11 cAMP-dependent protein kinase/PKA 41 1.00 IPI00554752
12 Cell division protein kinase 5/CDK5 44 1.00 IPI00023530
13 DLG1/SAP97/GKAP 7 1.00 IPI00552511
14 DLG2/PSD-93/Chapsyn-110 13 1.00 IPI00647950
15 DLG4/PSD-95 24 1.00 IPI00790650
16 Dynamin 59 1.00 IPI00887273
17 Glutamate receptor, ionotropic, AMPA 2 11 1.00 IPI00219216
18 Glutamate receptor, ionotropic, AMPA 3 9 1.00 IPI00298700
19 Glutamate receptor, ionotropic, NMDA 2A 3 1.00 IPI00029768
20 Glutamate receptor, ionotropic, NMDA 2B 6 1.00 IPI00297933
21 Glutamate receptor, metabotropic, 5 5 1.00 IPI00296244
22 Gα 13 24 1.00 IPI00290928
23 Gαi 1 20 1.00 IPI00337415
24 Gαi 2 27 0.97 IPI00748145
25 Gαi o 40 1.00 IPI00398700
26 Gαs 12 1.00 IPI00095891
27 Gβ 1 39 1.00 IPI00026268
28 Gβ 2 47 1.00 IPI00003348
29 Gβ 5 19 1.00 IPI00745232
30 Gγ 40 1.00 IPI00328128
31 Heat Shock Protein 70 12A 50 1.00 IPI00011932
32 Homer 1 21 1.00 IPI00003566
33 Inositol 1,4,5 Triphosphate receptor 5 1.00 IPI00333753
34 L-type calcium channel 10 1.00 IPI00219983
35 MAP Kinase 21 1.00 IPI00003479
36 MAP Kinase Kinase 23 1.00 IPI00219604
37 MAP Kinase Kinase Kinase Kinase 5 1.00 IPI00219510
38 nGEF/Neuronal guanine exchange factor 12 1.00 IPI00749021
39 Nitric oxide synthase, brain 8 0.99 IPI00746356
40 Phospholipase A2 8 1.00 IPI00220209
41 PKCα 28 1.00 IPI00385449
42 PKCγ 27 1.00 IPI00007128
43 PKCε 20 1.00 IPI00024539
44 Protein phosphatase 1 23 1.00 IPI00045550
45 Protein phosphatase 2 20 1.00 IPI00000030
46 Protein tyrosine kinase 2B/PYK 14 1.00 IPI00029702
47 Protein tyrosine phosphatase, receptor type D 8 1.00 IPI00375547
48 Protein tyrosine phosphatase, receptor type S 9 1.00 IPI00332271
49 Proto-oncogene tyrosine-protein kinase/Src 10 1.00 IPI00641230
50 Rap guanine nucleotide exchange factor 2/Rap GEF2 12 1.00 IPI00853219
51 Ras GTPase-activating protein/SynGap 17 1.00 IPI00177884
52 Ras-related protein Rab-10 11 1.00 IPI00016513
53 Ras-related protein Rab-3A 12 1.00 IPI00023504
54 Regulator of G-protein singaling 6/RGS 6 12 1.00 IPI00216329
55 Regulator of G-protein singaling 7/RGS 7 14 1.00 IPI00220661
56 Rho GTPase-activating protein/Rho GAP  11 1.00 IPI00020567
57 Rho guanine nucleotide exchange factor/Rho GEF 26 1.00 IPI00641543
58 Rho-Rac guanine nucleotide exchange factor/Rho-Rac GEF 17 1.00 IPI00291316
59 R-type calcium channel 4 1.00 IPI00218338
60 serine threonine kinase DCLK2 14 1.00 IPI00296360
61 SH3 and multiple ankyrin repeat domains protein 3/SHANK3 14 1.00 IPI00847618
62 Voltage-dependent anion-selective channel 21 1.00 IPI00216024
63 Voltage-gated potassium channel 14 1.00 IPI00021088
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Supplemental Figure 2-1.  Proteins identified by 2DLC-MS/MS analysis. (A, B and 
C) Protein identifications were grouped by GO with respect to Cellular Compartments 
(A) Biological Processes (B) and Molecular Functions (C). Each categorization shows 
groups of proteins that may be associated with the PSD and the ones that are likely to 
be contaminants. (D and E) Protein identifications were compared to the results of 
previous studies. (D) Sequences from the 63 confirmed proteins were compared to 
those from Trinidad et al. and Dosemeci et al. data sets with the criteria defined as 
sequence homology of >90%.  (E) Sequences from the 63 confirmed proteins were 
compared to those from Trinidad et al. and Dosemeci et al. data sets by identification 
based on IPI description; all but 10 were found in one or both data sets.     
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Supplemental Figure 3-1. Distribution of Heavy/Light Ratios and Unique Peptide 
Pairs. The signal ratio of [13C6]Lysine-Labeled peptides  to unlabeled peptides was 
calculated. A, shows the distribution of ratios for peptides unique to a single protein 
group.   B, shows the distribution of Unique [13C6]Lysine-Labeled peptides observed 
per protein.  C, shows depicts representative chromatographic peaks of light and heavy 
peptides from four peptides with different expression values. Note that the y axis is 
log10. This figure highlights the similarity in relative protein expression between the 
standard and analyte proteomes.  
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Supplemental Figure 3-2. Technical precision of peptide measures.  To assess 
technical precision in peptide measure, four 30 μg aliquots of a human IM 
fraction were individually mixed with 15 μg [13C6]brain ISTD and analyzed by 
LC-SRM/MS with triplicate injections. Peptide measure CV was calculated and 
the average of these taken for the four repeated preparations. A, shows this 
average CV number was plotted against the average integrated area of each 
peptide from all preparations and injections.  While CV correlates with peak area 
(R2 = .71), the CV values but four peptides are under 20%. 
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Supplemental 
Figure 3-3. 
Distribution of 
variance in protein 
quantification by 
fraction. CVs for 
protein enrichment 
values were 
calculated for each 
fraction, and the 
distribution plotted 
in 5 unit bins up to 
30%.   A, total 
homogenate (H). B, 
synaptosomal 
fraction (SF).C 
vesicular (V).D, 
papasynaptic 
fraction (P).E, 
postsynaptic density 
(D). The distribution 
shape is often 
similar between the 
two species, but the 
center is often lower 
in preparations from 
mouse tissue. 
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Supplemental Figure 3-5. Differences in septin enrichment 
are not explained by postmortem interval. We compared 
enrichment values for septin proteins in three fractions. A show 
enrichment in human parasynaptic fractions (H P) postsynaptic 
density (H D) and synaptosomal (H SF). B, shows the same for 
fractions prepared from mouse, M P, M D and M SF. C, shows 
measures for septin proteins over increasing postmortem interval 
(PMI) in D fractions prepared from mouse tissues.  
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#  Sex  Race Age PMI Rx Batch
1  F  W 70 10.5 N 1
2  F  W 76 9 S 1
3  M  B 63 5 N 1
4  M  W 71 12 S 1
5  F  W 85 11 N 1
6  F  W 79 17 S 1
7  F  W 72 4 N 1
8  F  W 77 11 S 1
9  M  W 98 15 N 1
10  M  W 89 15 S 1
11  M  W 86 7 N 1
12  M  W 81 9 S 1
13  F  W 91 11.5 N 2
14  F  W 96 12.5 S 2
15  M  W 70 19 N 2
16  M  W 78 19 S 2
17  F  W 92 5 N 2
18  F  W 88 7.5 S 2
19  F  W 74 3.5 N 3
20  F  W 76 9.5 S 3
21  M  W 90 6 N 3
22  M  W 95 8.5 S 3
23  F  W 72 7 N 3
24  F  W 72 11.5 S 3
25  F  W 88 7 N 3
26  F  W 77 5.9 S 3
27  F  W 80 15 N 3
28  F  W 80 16 S 3
29  F  W 81 8 N 3
30  F  W 83 7.5 S 3
 
 
 
 
 
 
 
Supplemental Table 4-1. Demographics. # = internal 
identification number. Sex, F = female, M = Male. 
Race, W = Caucasian, B = African American. Age (y), 
PMI = postmortem interval in hours, Rx = diagnosis, N 
= normal control, S = schizophrenia. Batch = cohort 
the sample was prepared with, see methods. 
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Supplemental Figure 4-1. Comparison of enrichment protocols. This figure contrasts 
the enrichment values for representative pre- and post- synaptic proteins in PSD 
enrichments prepared from the three human and three mice using the method described in 
chapter 3, denoted here as “Full” and PSD enrichments prepared from five humans and 
five rhesus monkeys using the abridge protocol described in Chapter 4, denoted here as 
“Abr”.  It is important to know that rhesus monkey brain tissue was dissected from cold 
saline profused animals, while tissue from mice was vivisected at body temperature.  Thus 
differences in enrichment protocol and dissection protocol likely contribute to differences 
between these two groups. Fold enrichment values are calculated by dividing the protein 
value from the PSD enrichment by protein value from total homogenate.  The fold 
enrichment of PSD95 (DLG4), CAMK2A and CAMK2A is similar across human and 
monkey preparations, while glutamate receptors are more enriched in Abr monkey 
compared to Abr human. Presynaptic/SNARE complex proteins are un-enriched by all 
proticoals in all animals. While there are differences in enrichment of PSD proteins, likely 
owing to PMI confounds in humans, different enrichment protocols and dissection 
methods, all four of the preparations were enriched, to some extent, for postsynaptic 
glutamate receptors, PSD95 and kinases, excluding presynaptic/SNARE proteins.Human 
Full = three human subjects described in Chapter 3, Human Abr = five control subjects 
from Chapter 4, batch 3, Monkey Abr = the five vehicle animals described in Chapter 4. 
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Supplemental Figure 4-2. Distribution of protein levels and protein enrichment 
values.   
A. Beta tubulin-normalized protein levels, total homogenate from 15 control subjects.  
B. Protein enrichment values, PSD enrichments from 9 control subjects. 
C. Protein enrichment values, PSD enrichments from 6 control subjects. 
D. Beta tubulin-normalized protein levels, total homogenate from 14 SCZ subjects.   
E. Protein enrichment values, PSD enrichments from 8 SCZ subjects. 
F. Protein enrichment values, PSD enrichments from 6 SCZ subjects. 
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Supplemental Figure 4-3.  PSD protein enrichment is elevated in schizophrenia 
in both the 9 and 6 pair cohorts. Biochemical fractions enriched for PSDs were 
prepared from the LPFC of 9 SCZ subjects and matched controls. Quantitative 
measures of 107 proteins were assayed therein by LC-SRM/MS. Enrichment values 
for 104 of these proteins were calculated by divideing un-normalized protein 
measures in PSD enrichments by un-normalized protein measures in whole cell 
homogenates. The average protein enrichment value was taken for each group and the 
SCZ average divided by the control average (SCZ/CTL) to obtain a ratio of 
dysregulation for each protein. A, shows the distribution of these dysregulation ratios 
for 6 pairs. C, shows the distribution of these dysregulation ratios for 9 pairs. B, 
shows average protein enrichment values from 6 pairs of human tissue, which were 
significantly increased in PSD preparations from disease tissue, (P < .0001). D, shows 
average protein enrichment values from 9 pairs of human tissue, which were 
significantly increased in PSD preparations from disease tissue, (P < .0001). Note, D. 
differs from Figure 4-3B as subject #22, found to be an outlier in the enrichment 
dataset, is included here (B. &D.) but not in Figure 4-3B. CTL = control, SCZ = 
schizophrenia. Error bars are standard error of the mean. 
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Supplemental Tables 4-2. Protein Enrichment differences with a P-value > 2. 
A. Proteins with elevated enrichment values in PSD enrichments from 6 pairs.  
B. Proteins with decreased enrichment values in PSD enrichments from 6 pairs.  
C. Proteins with elevated enrichment values in PSD enrichments from 9 pairs.  
D. Proteins with decreased enrichment values in PSD enrichments from 9 pairs. 
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Supplemental Figure 4-
4. Enrichment values 
of five functional 
protein groups are not 
regulated by diagnosis. 
Biochemical fractions 
enriched for PSDs were 
prepared from the LPFC 
of 9 schizophrenic 
subjects and matched 
controls and rhesus 
monkeys treated with 
different neuroleptics 
and fold enrichments 
values calculated. These 
proteins were manual 
sorted into five groups 
by function: A. and B, 
neuronal cell adhesion, 
C. and D, spectrin and 
ankrin, E. and F, protein 
phosphatases, G. and H, 
presynaptic/SNARE 
complex, I. and J, 
septins. The left column 
(A, C, E, G & I) show 
enrichment values from 
SCZ and control 
subjects while the right 
column (B, D, F, H & J) 
shows values from 
rhesus monkey treated 
with neuroleptics. CTL 
= control subjects, SCZ 
= schizophrenia, Veh = 
vehicle, Cloz = , L Hal = 
low dose haloperidol 
and H Hal = high dose 
haloperidol. Error bars 
are standard error of the 
mean. 
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Supplemental Figure 4-7. Unsupervised hierarchical clustering, with Pearson's Correlation as the 
similarity metric, was utilized to group subjects and selected PSD proteins by non-normalized protein 
values measured in PSD enrichments. Subjects with different diagnoses were segregated into two 
groups near perfectly. C = control, S = schizophrenia. B, shows an identical analysis of the same 
subjects and proteins using non-normalized protein values measured in whole tissue homogenates. C = 
control, S = schizophrenia. C, shows an identical analysis of the same subjects and proteins using non-
normalized protein values measured in PSD enrichments from rhesus monkeys. V = vehicle, HH = high 
does haloperidol. Proteins are identified by official gene symbol. 
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